bristolmyers squibb company annual report nopqr f c u park avenue new york ny telephone wwwbmscoms c k h l e r n f r n common stock dividend reinvestment plan environment foundation copyright bristolmyers squibb mission ticker symbol bmy registered stockholders stock diversity reports bristolmyers squibb company new york stock exchange must held name copies companys rights reserved companys mission pacific stock exchange hold shares recent reports product names appearing companys stock may participate bristolmyers squibb foundation throughout italics extend enhance human life annual meeting stockholderpaid dividend sustainabilityenvironmental bold caption copy providing highestquality pharmaceutical stockholders reinvestment plan drip programs diversity registered trademarks tuesday may includes safekeeping efforts write bristolmyers squibb company related health care products hotel dupont saleofstock feature corporate affairs one subsidiary companies th market streets hold fewer shares bristolmyers squibb company global products referred wilmington de still eligible participate park avenue herein registered pledgeto patients customers safekeeping saleofstock new york ny approved us trademarks unless stockholder features well direct specifically noted otherwise employees partners services programs registration option copies companys abilifyis trademark otsuka inquiries concerning eeo reports available pharmaceutical company ltd shareholders neighbors adenoscanis trademark stockholder accounts stock stockholders upon written fujisawa healthcare inc world serveto act belief transfer matters including free copy companys request address avapro avalide plavixand address changes elimination annual report securities iscoverare trademarks sanofi priceless ingredient every product duplicate mailings dividend exchange commission information interest synthlabo sa reinvestment see next column fiscal year stockholders potential corzide delestrogencorgard honor integrity maker direct deposit dividends ended december investors including information florinefare trademarks king directed visit wwwbmscominvestors companys products pharmaceuticals inc erbituxis trademark companys transfer agent programs also available imclone systems incorporated registrar reports may also companys web site glucophage ir glucophage mellon investor services obtained sending request wwwbmscom xr glucovanceand metaglipare challenger road secretary registered trademarks merck ridgefield park nj bristolmyers squibb company sant sas associate merck wwwmelloninvestorcom park avenue kgaa darmstadt germany within us new york ny moisturel duricefand estrace trademarks galen chemicals outside us limited tdd telephone service solageis trademark hearing impaired galderma sa within us vaniqais trademark women outside us first healthcare inc viactivis trademark mcneil ppc inc cover keiichi nagano sturgis michigan pictured wife reiko keiichi colorectal cancer patient enrolled clinical trial erbitux cetuximab help fight cancer opposite top melody vernali process scientist bristolmyers squibb pharmaceutical research institute wallingford connecticut working colleagues create next generation anticancer therapies designed photographed written typeset bristolmyers squibb corporate affairs department printed recycled paperf c u turn maybe certainty transform idea breakthrough therapy energize company people true leaders make difference people need better medicines take keiichi nagano sturgis michigan pictured cover wife reiko battled colorectal cancer years today credits health loving support reiko daughters tomoko naoko participation clinical trial erbitux cetuximab developed bristolmyers squibb imclone systems incorporated approved us food drug administration february erbitux help family doctors nurses says hope normal life enjoy bristolmyers squibb remained focused erbitux cancer therapies well additional areas critical unmet medical need described report people like keiichi enjoy life ride motorcycles like continue journeys love pages follow learn bristolmyers squibb sharpening focus defining future helping create healthier future people worldwide comes mission extend enhance human life focusedas never bristolmyers squibb company annual reportf c u u r c k h l e r year bristolmyers squibb earned billion continuing operations worldwide net revenues billion total net sales increased percent including effect foreign exchange among leading products net sales pravachol cholesterollowering medicine grew percent billion net sales plavix antiplatelet good year company three important new therapy avaproavalide treat ments hypertensionwhich bristolmyers squibb medicines helping thousands people codeveloping comarketing schizophrenia hivaids cancer potential sanofisynthlaboincreased percent billion touch thousands th year row paid dividends percent million respectively stockholders third consecutive year looking newer products dividend payments exceeded billion across pharmaceutical total revenue abilifya treatment schizophrenia health care portfolios well geographies codeveloping copromoting realized broadbased sales earnings growth made otsuka pharmaceutical co ltdreached nearly million significant progress strengthening financial internal controls first full year market across pharmaceutical implementing fundamental changes company related health care businesses eight address opportunities challenges ahead products product lines realized global net sales excess million additional products achieved net sales greater million eighteen brands grew doubledigit rates addition delivering solid financial performance met key objectives year may recall set following goals successfully launch new products grow key inline products franchises invest businesses pipeline continue putting right leaders place strengthen compliance processes structures well financial controls accounting things also initiated critically important change process build momentum achieved prepare challenges opportunities ahead help guide us process implementing new strategy narrows focus sharply mission areas medical need truly make difference patients future chosen focus theme annual report highlight strategy launching new products would like begin discussion achievements erbitux novel cancer treatment codeveloping copromoting imclone systems incorporated may recall committed bring important product devel opment regulatory review pleased following steps erbitux received marketing approval us food drug administration february annual report bristolmyers squibb companygrowing key products erbitux represents significant step forward fight advanced colorectal cancer disease effective abilify reyatazcontributed strength treatment options us bristolmyers squibb excited importantly tremendous potential going forward principal potential new medicine help patients erbitux growth drivers year pravachol plavix avaproavalide serves important bridge wellestablished cancer well sustivaand cancer treatment paraplatin net sales sustiva therapies promising oncology pipeline opportunities grew percent million paraplatinincreased would like thank colleagues especially oncology percent million altogether worldwide pharmaceutical areaas well people imclonefor dedication resiliency net sales increased percent billion focus critical making erbitux reality patients need health care businesses convatec reported solid net sales undoubtedly hear read promising medicine gains two major product lines ostomy grew percent move quickly make available patients explore million wound therapeutics increased percent potential additional uses fight cancer million medical imaging business net sales cardio approval erbitux bristolmyers squibb introduced vascular imaging agent cardiolitegrew percent million net three important new medicines month period compared sales mead johnson nutritionals business increased percent recent average companies industry slightly billion international nutritionals net sales grew percent one new drug launch per year achievement clearly illustrates recently divested adult nutritionals line allowing mead johnson progress making developing latestage pipeline focus exclusively products infants children area turning newer products abilify already captured recognized market leader significant sharemore percent dateof weekly new prescriptions antipsychotic class thanks strong sales peter r dolan first year market abilify ranks among successful new product launches date entire pharmaceutical industry chairman abilify gained additional indication longterm treatment chief executive officer schizophrenia also submitted filing indication treatment acute mania patients bipolar disorder abilify growing presence several countries outside us received recommendation marketing approval europe february reyataz treatment hivaids introduced us july date garnered strong percent share weekly new prescriptions protease inhibitor category first protease inhibitor onceaday dosing reyatazcan help hivaids patients reduce pill burden important addition growing virology business also includes sustiva videxec zerit march received marketing approval reyataz europe looking forward introducing international markets bristolmyers squibb company annual reportgrowth strong across geographies well us pharmaceutical bristolmyers squibb notable record pursuing successful net sales rose percent billion international pharmaceutical licensing arrangements supplement pipeline many net sales increased percent billion inclusive foreign exchange arrangements led fruitful codevelopment copromotion us total net sales plavix rose percent avaproavalide comarketing agreements continue complement sustiva paraplatinand pravacholalso growing doubledigit rates pipeline additional licensed products europe middle east africa region pharmaceutical also entered new alliance lexicon genetics business continued trend robust growth percent solid provide us potentially valuable drug discovery targets neuro performance due large part strong net sales pravachol plavix science area comprehensive network alliances partnerships avaproavalide sustiva grew percent range includes collaborations approximately companies year asiapacific region pharmaceutical net sales research institutions increased percent driven part strong net sales japan taxol meeting important objectives cancer treatment grew percent sales taxolalso increased percent europe although product lost data exclusivity integrity transparency critical continued future third quarter global taxolsales million success made great progress toward goals strengthen ing financial reporting compliance efforts structures investing future communicated employees first priority must turning research development goals advanced drug full compliance letter spirit rules regulations pipeline significantly transitioned two potentially break governing company must highest standards compounds phase iii including muraglitazar dual ppar business personal medical ethics accordance values agonist diabetes ixabepilone novel epothilone cancer expressed bristolmyers squibb pledge eight promising compounds later stages development past year senior management direction audit seven discovered laboratories committee continued identify implement actions improve next months intend submit three latestage effectiveness disclosure controls procedures well products regulatory approval including entecavir hepatitis b internal controls financial reporting finance area created abatacept ctlaig rheumatoid arthritis muraglitazar roles financial controller operations controller named invested billion companywide research devel two highly experienced individuals positions working closely opment expect boost spending drug development chief financial officer acted implement stringent percent range accelerate promising latestage pipeline financial controls processes providing enhanced education internal growth vital future success continually training finance colleagues constantly reviewing evaluating pursuing external opportunities leverage accounting policies procedures aim ensuring full strengths licensed three products longacting insulin com compliance applicable regulations laws pound basulin flamel technologies inhaled insulin product largely result actions throughout identified qdoseboth earlystage compounds enhance diabetes recorded various charges adjustments correct accounting related franchiseas well edifoligide phase iii compound corgentech prevent vein graft failure bypass surgery build leadership atherosclerosisthrombosis area h g h l g h first quarter bristolmyers squibb research bristolmyers development center squibb foundation commits opens singapore help reinforcing companys hungarian hospice commitment rd foundation support national association country psychosocial counseling female executives throughout asia bristolmyers squibb cancer patients names bristolmyers recognized families squibb one mead johnson several groups top companies nutritionals launches environmental reporting executive women enfamil iron including named enfapro south korea top environmental licensing agreement reporter us signed pharmatop headquartered companies french company coalition injectable environmentally acetaminophen responsible economies added abilify aripiprazole calvert social index launched mexico list socially receives marketing responsible companies clearance australia annual report bristolmyers squibb companyprior periods reviewed items decided restate previously grants totaling nearly million programs nine issued financial statements based cumulative impact countries southern western africa support research treatment continue efforts strengthen financial internal controls education community outreach targeted women children appointed new seniorlevel chief compliance officer directly affected hivaids reporting directly general counsel indirectly fifth year secure futurecontinues focus working closely compliance professionals across company developing sustainable models addressing health social also put place structures processes help make clear consequences pandemic replicating models employees obligations rights compliance area resourcelimited settings key programs effectiveness close enable reporteasily without fear retributionany partnerships developed among private sector governmental concerns may nongovernmental organizations universities medical institutions senior leadership changes include appointment anthony c among others hooper president us pharmaceuticals member executive major milestone opening pediatric hivaids committee tony seasoned leader proven record success center botswana southern african country highest hivaids growing key businesses franchises recently served infection rate world percent infant president medicines business europe middle east africa deaths related hiv first center subsaharan africa help ensure critically important us pharmaceuticals based early success recently committed build second unit remains central driver growth leadership going forward center continent near future also promoted batrice cazala position president europe another project illustrates broad reach companys middle east africa batrice extensive experience building mission remarkable event october helped people leading brands across europe instrumental taking across us confront fears questions cancer called business region next level achievement success bristolmyers squibb tour hope event nonstop mile coasttocoast bicycle ride extraordinary dedicated building sustaining better world men women goal spread message hope bristolmyers squibb pledge defines success terms knowledge fighting ultimately defeating cancer especially values uphold live daily work addition financial encouraging diagnosed disease participate business performance measure success well realize clinical trials new anticancer therapies mission extend enhance human life broadly altogether charitable cash contributions health research interpret mission beyond providing quality medicines education projects exceeded million also donated health care products nearly million medicines products people bristolmyers squibb foundation supports wide range communities need innovative health research education initiatives exemplify made good progress environmental health safety efforts mission extend well beyond business obligations including sustainability goals among engaged citizens world among initiatives secure broadest industry goals commit us pursue range future largest corporate commitment kind address policies practices create cleaner environment safer work staggering hivaids crisis subsaharan africa provided place take leadership role industry advance activities second quarter bristolmyers squibb third quarter foundation us food partnersthe china drug administration foundation hepatitis fda approves reyataz prevention control atazanavir market chinese ministry bristolmyers squibb ingthe first oncedaily healthcomplete imclone systems protease inhibitor final phase three incorporated file year biologics license mead johnson acquires initiative bring application cafcit caffeine citrate hepatitis b vaccinations fda approval injection oral infants two erbitux cetuximab suspension provinces rural china fdaapproved shortterm company agrees treatment premature first pediatric hivaids license inhaled infants potentially center africa insulin product lifethreatening opens botswana funded treat diabetes breathing bristolmyers squibbs qdose joint venture disorder secure future microdose program company technologies inc commits fund second quadrant drug center africa delivery ltd children hivaids bristolmyers squibb company annual reporta focused strategy future relationships specialists well primary care physicians hopeful times people looking better medicines also involved treating patients disease areas help live healthier longer rewarding lives therapies aspects strategy support two priority areas like erbitux abilify reyatazrepresent significant steps forward example biologicslarge molecule compoundswill assume treating terrible diseases kill disable millions people every year prominent place among new therapy options promising leading product pravacholthe extensively studied statin drug growing area requires investments highly specialized technology strong efficacy safety profile exceeded facilities also continue invest key parts business statincontinues important treatment option patients including new product launches inline portfolio pipeline high cholesterol coronary artery disease drug pipelines hold keeping dividend priority means spending promise effective treatments near long term areas must held check even cut back policy makers taking positive steps ensure people greater excited pipeline growth opportunities access best medicines objective strongly support promote facing challenges affect overall performance medical science public policies must change reflect next years period several larger products transformations society businesses must continually adapt change lose exclusivity us elsewhere result estimate meet expectations needs customers stockholders aggregate net sales products decline much billion employees stakeholders bristolmyers squibb see approximately additional billion billion opportunities challenges ahead require us become different years kind companya focused organization better able much revenue loss less offset growth seize initiative turning scientific advances innovative pharma revenues major inline products plavix avaproavalide ceuticals health care products areas significant unmet newer medicines erbitux abilify reyataz medical need want health care leader tomorrow well pipeline products however many newer must begin transformation process today products licensed high costs associated launch drive change implementing new strategy building manufacture initial promotion gross margins pressured fundamentally different kind company first read period report concentrating disease areas need great next years portfolio evolves new strategy better treatments either already strong positions enable us maximize product pipeline opportunities also cancer hivaids psychiatric disorders atherosclerosisthrombosis addressing exclusivity issues pipeline delivers hope diabetesor build future strengths based promising pipeline emerge process position greater strength opportunities emerging areas include alzheimers disease hepatitis poised deliver sustained sales earnings growth extended obesity rheumatoid arthritis solid organ transplantation periodwhen exposure additional patent expirations second major aspect new strategy relates business greatly reduced specifically marketing sales approaches specialists playing course planning uncertain future never easy even greater role decisions related patient treatment care work many risks unknowns profoundly affect particularly disease areas focusing efforts reason recasting business model help us build even closer h g h l g h fourth quarter working mother magazine names bristolmyers squibb fifth time one top best bristolmyers squibb companies working brazil included mothers third exclusive list straight year also choicedm top companies work sixth consecutive year comprehensive line published exame company diabetic care products magazinea leading included among launched business publication magazines ranking best companies bristolmyers squibb bristolmyers squibb flamel technologies corgentech inc sa enter licensing announce agreement commercialization jointly develop agreement develop commercialize market basulin corgentechs first controlledrelease edifoligide novel convatec introduces unmodified human cardiovascular treatment esteem synergy insulin developed ostomy system oncedaily injection us launched patients type europe type diabetes annual report bristolmyers squibb companyoutcomes example two generic drug companies currently challenging key patent plavix expires however standing still looking back never options bristolmyers squibb contrary see job building toward better future creating future optimism resolve indeed many reasons confident prospects bold vital mission continues drive us succeed enduring code ethics values guides choices dedicated employees shown believe company vital role play advancing health wellbeing people world excellent products pharmaceutical pipeline extend enhance human life also many thousands stockholders share vision selected laterstage compounds better world essential success closing would like thank stockholders continuing support goals current march pivotal time bristolmyers squibb employees also deserve compounds later stages development thanks gratitude hard work enduring commitment bristolmyers squibbs pipeline include mission success would like express sincere appreciation board directors ongoing support abatacept ctlaigfor rheumatoid arthritis counsel continue keep closely informed progress novel compound phase iii work diligently toward building great future company dpp inhibitor diabetes novel oral compound phase ii backup compound development peter r dolan chairman chief executive officer edifoligide ef decoy prevention vein graft failure following march coronary artery bypass graft peripheral artery bypass graft surgery novel treatment phase iii entecavirfor hepatitis b compound phase iii ixabepilonefor cancer novel epothilone phase iii leay prevention solid organ transplant rejection novel agent phase ii bristolmyers squibb muraglitazarfor diabetes medical imaging enters dual ppar agonist phase iii backup compound us agreement development fujisawa healthcare inc copromote adenoscan razaxabanfor venous thrombosis adenosine injection novel factor xa inhibitor phase ii backup compounds nations leading development pharmacologic stress agent used myocardial perfusion imaging lance armstrong company forms members alliance lexicon bristolmyers genetics neuro squibb tour ofhope science drug discovery team member team seeks raise plavix awareness clopidogrel cancer research bisulfate clinical trials reaches unprecedented cross billion country cycling journey us sales bristolmyers squibb company annual reportf c u c n c e r hings looked pretty good thus began fiveyear roller yet january run daryl doyle back july coaster ride daryl initially treatment options age happily married treated surgery followed end rope admits teenage son three school chemotherapy colon cancer doctor told age daughters recurred first liver clinical trial erbitux loved mostteaching chemistry colon finally lungs cetuximab developed kettering university flint never lost bristolmyers squibb imclone michigan suddenly following focus cancer systems incorporated erbitux discovery blockage colon says stand back assess monoclonal antibody treatment life changed forever whats important family designed target block six words surgeon well comes first also want epidermal growth factor receptor know cancer best possible teacher egfr expressed surface daryl recognized ketterings certain cancer cells outstanding teacher year erbitux last chance promising cancer daryl says march treatments sometimes began weekly treatments six weeks ct scan showed come unlikely places significant regression cancerous ixabepilone novel epothilone lesions since lesions phase iii clinical trials stabilized derived bacteria found erbitux approved february us food garden soil drug administration fda use combination taxol makes difference japan irinotecan treatment patients egfrexpressing bristolmyers squibbs breakthrough cancer prevalent japan patients previously treatment taxolpaclitaxel first practically effective option treatment irinotecanrefractory metastatic taxane available patients japan says hiroya takiuchi md assistant professor colorectal cancer single approved use country department internal medicine osaka agent patients intolerant however didnt take longin fact took medical college clinical trials conducted six monthsfor taxolto lead japan taxolachieved positive results irinotecan takes market still today treating gastric cancer japan success taxolin japan first country approve chemothera credited companys strategic approach peutic agent indication says developing medicine meet specific dr takiuchi encouraging see needs japanese patients backed patients experiencing improvement results clinical trials conducted exclusively daily activities receiving japan supported results studies treatment taxol conducted countries taxolwas demand taxolcontinues initially approved treatment grow japan annual rate ovarian cancer followed breast lung percent clinical trials currently cancer way seeking additional indications could even patients enhanced methods treatment japan example gastric cancer leading may help dr takiuchi physicians cause cancer death gastric cancer improve lives even patients annual report bristolmyers squibb companytargeted approach cancer treat phase iii clinical trials following success cancer ment erbitux important anticipate ixabepilone erbitux daryl accepted new always fighting new treatment option patients approved would consolidate responsibilities director fighting fighting says frank pasqualone senior vice global oncology position several ketterings center excellence says daryl doyle president oncology also innovative anticancer agents teaching learning teaches chemistry brilliant example unrelent including taxanes epothilones erbitux allowed kettering university ing commitment oncology small targeted moleculesfollow continue focus flint michigan today company offers ixabepilone clinical development important things life lately anticancer medicines daryl doyle com says given hope erbitux ally patients worldwideincluding panys focus oncology longer mainstays therapy enabled one person family fighting alone paraplatincarboplatin taxol continue focusing whats paclitaxel ifexifosfamide important lives vast experience devel oping delivering important cancer therapies says renzo canetta md vice president oncology clinical design evaluation following erbitux robust pipeline promising compounds discovered bristolmyers squibb scientists example ixabepilone novel epothilone entered bristolmyers squibb company annual reportf c u h v j esse hairston really likes jesse admits mistakenly june jesses doctor knock pins neighbor avoided treatments long prescribed reyatazatazanavir hood bowling alley nearly simply saw friends recently approved years ago jesse treated still dying us food drug felt knocked downfirst paid price waiting administration fda learned former partner complications weight first oncedaily protease inhibitor dying fullblown aids loss thrush infection used combination thenby discovery year later signaled weakened immune antiretroviral agents dont let hiv hiv positive system finally treatments treatment hiv infection positive slow yearold security officer began side effects also prescribed zeritstavudine says jesse hairston lives shaker heights ohio significant intestinal another medicine work bowl go recalls devastated hurt infection month reyatazoffers patients potential movies feel family members reacted lipid problems says benefits including minimal impact fortunate told going addition little fat lipid levels oncedaily reyataz part die soon body distributed dosing reyatazwere hiv combination therapy properly leaving areas way goal normally going places leader onceaday therapy says didnt belong timothy ravenscroft vice presi dent virology global franchise two company medicines also allow oncedaily dosing part hiv combination therapy videxec didanosine delayed release capsules sustiva annual report bristolmyers squibb companyefavirenz sustivathe first growing pipeline drugs oncedaily hiv medication ever development companys demonstrated uninterrupted pharmaceutical research institute growth demand patients developing number new physicians since compounds including two approved marketing potential firstinclass drugs fda initially could represent significant advances marketed dupont pharma treatment hivaids ceuticals growth accelerated attachment inhibitor bristolmyers squibbs acqui integrase inhibitor attach sitionof dupont pharmaceuticals ment inhibitor advanced thereby sustivain phase ii clinical trials bristolmyers squibb says jeffrey hatfield integrase inhibitor earlier company offering senior vice president virology development sustivahas become cornerstone today jesse able work oncedaily oral medicines combination drug treatment enjoy knocking pins major treatment regimens hiv says reyatazis advancing class hiv bristolmyers squibb fight disease strong portfolio medicines help address needs people hivaids well accelerating access initiative percent worlds estimated aai recognizes many obstacles million people living hivaids reside achieving sustainable access hiv treatment developing countries although effective way respond cure medical care industrialized world collaborative efforts many different players significantly transformed extended patients estimated people africa lives challenge bring receiving treatment result transformation developing world initiative numbers small relative course providing medicines need aai demonstrated hiv enough said lee jongwook md director treatment possible resourcelimited general world health organization settings says mariclaire payawal senior recent new york press conference aids director global access program aai investing treatment aids also means catalyzed effortsbuilding political strengthening health systems commitment national governments bristolmyers squibb community advocacy leadership researchbased pharmaceutical companies un multilateral agencies joined forces united nations un find sustainable solutions bring agencies establish accelerating access necessary medicines need initiative aai landmark publicprivate global access program collaboration expand access hiv care bristolmyers squibb makes videxand zerit treatment developing world available profit subsaharan africa bristolmyers squibb company annual reportf c u p c h r c r e r bilify aripiprazole thats good news bristolmyers still beneficial may novel treatment schizophrenia squibb even better news patients schizophrenia developed marketed partner patients schizophrenia abilify may also great potential shipwith otsuka pharmaceutical abilify helps people schizo use treating psychiatric co ltd introduced phrenia control symptoms disorders determine full us late yet already enabling many lead range benefits abilify may neil richtand md phd hailed one moreproductive morenormal offer bristolmyers squibb associate professor successful launches history lives says jeffrey lieberman md otsuka launched psychiatry university pharmaceutical industry vice chairman psychiatry comprehensive research cincinnati left professor psychiatry pharma development program one hugh eakin new cology university north areas currently explored richmond ohio carolina chapel hill bipolar disorder persons mood swings like unpredictable pendulum mania depression bristolmyers squibb filed approval abilify us food drug administration fda annual report bristolmyers squibb companyparticularly lifedisrupting aspect thing expecting new mechanism action could bipolar disorder known acute everyone else enrolling represent next generation mania preparations filing clinical trial abilify antidepressants potentially side us also way could react situations without better efficacy better safety neil richtand md phd overreacting says profile current therapies associate professor psychiatry acute mania first target says frank yocca phd university cincinnati trials affective disorders executive director neuro run several abilify clinical trials arena weve clearly science clinical design acute mania past years successful says elyse stock md evaluation abilifys potential treatment vice president abilify global chance acute mania highly promising development champion develop abilify says saw improvement aggressive program clinical major reason joined symptoms many clinical trial investigations evaluate bristolmyers squibb participants improvement illnesses fall within says jack grebb md vice also notable rapid spectrum affective disorders president neuroscience clinical ityof response well abilify backed growing design evaluation patients tolerated medication pipeline compounds discovery group working one clinical trial patients development psychiatric disor next steps develop hugh eakin chef father ders example researchers new drugs treat psychiatric million people two teenage daughters lives discovered novel potentially disorders effectively industrialized new richmond ohio hugh firstinclass crf corticotropin diagnosed bipolar disorder releasing factor type receptor countries suffer depression antagonist crf plays major bipolaror says virtually shut role bodys response manic depressive live stress appears linked disorder mania adds multitasking depression anxiety crf exponentially trying every type receptor antagonists results debilitating new alliance mood swings spurred successful launch abilify francis cuss md senior vice president drug aripiprazole bristolmyers squibb discovery drugs resulting alliance reaffirmed commitment neuroscience enter clinical trials first option research via alliance lexicon genetics assume full responsibility clinical devel incorporated late december opment commercialization alliance lexicon contribute consider bristolmyers squibb drug discovery targets neuroscience ideal partner lexicons pipeline provide bristolmyers squibb drug discovery efforts neuroscience exclusive access future neuroscience says arthur sands md phd discoveries lexicons genome screen lexicons president chief executive lexicons program discover physio officer bristolmyers squibb logical functions genes provide rapidly growing franchise neuroscience alliance strategic advantage believe set stage greater identifying key drug targets human commercial success products emerging genome neuroscience indications says alliance bristolmyers squibb company annual reportf c u h e r c l e r h r b therosclerosis occurs atherothrombosis occurs fatty plaque consisting choles fatty plaque ruptures causes terol material builds platelets blood form clot walls artery like rust artery top ruptured pipe condition wellknown plaque clot restrict many often referred even block blood flow hardening arteries organ like heart brain atherothrombosis stiffening effect plaque clotting condition known responsible arteries one conditions thrombosis focus much cholesterollowering pravachol current investigation cardiology quarter pravastatin sodium helps fight become clear deaths worldwide added diet people blood clot formation central atherothrombotic coronary heart disease potentially deadly conditions clots restrict know cousin athero like heart attack stroke thrombosis equally insidious says deepak l bhatt md blood flow even dangerous indeed director interventional heart according world health cardiology fellowship program brain organization major manifes cleveland clinic tations atherothrombosis cleveland ohio heart attack stroketogether one largest clinical represent number one killers research programs ever developed world pharmaceutical product involving trials bristolmyers squibb medical imaging innovators heart patients several years bristolmyers squibb medical imagings clinical studies way supporting bristolmyers squibb taking steps vision develop unimagined innovations potentially expanded indications uses expand treatment options see ever deeper heart vasculature definityand cardiolite addition atherothrombosis patients playing vital role management patients pipeline new molecular imaging agent coronary artery disease innovative cardio targets vulnerable atherosclerotic plaquea key risk atherothrom vascularimaging products complement medicines indicator cardiovascular diseaseas well bosis bristolmyers squibb used treat heart disease related conditions nextgeneration pharmacologic cardiac partner sanofisynthlabo cardiolitekit preparation techne stress agent could used conjunction tiumtcm sestamibi injection cardiolite discovering antiplatelet successful radiopharmaceutical ever sold along contributing companys agent plavix clopidogrel bisulfate history nuclear medicine enables doctors growing leadership atherosclerosis also marketed iscover simultaneously assess heart blood flow thrombosis vision business also function via images single noninvasive aligns least two disease areas countries may test patients normal cardiolitestress test importance company diabetes help reduce risk greaterthan percent likelihood obesity says cory zwerling future events experiencing heart attack cardiac death president bristolmyers squibb medical within year tested definityvial imaging medical conditions including heart perflutren lipid microsphere injectable significant cardiovascular implications attack stroke suspension ultrasound contrast agent anticipate products patients used echocardiography enhancement continue make important suboptimal cardiac images help provide contributions areas earlier definitive diagnoses annual report bristolmyers squibb companyplavix available inhibitormay help prevent deep annually says adrienne ross patients since physicians vein thrombosis condition pharmd vice president global already prescribed plavix involves formation potentially brand champion estimated either alone aspirin lifethreatening blood clots percent grafts fail deepak l bhatt md reduce risk future cardio veins compound came within first year reducing director vascular events company acquisition number vein graft failures interventional million people worldwide dupont pharmaceuticals represents important area cardiology fellowship says brian gavin phd medical also phase iii development unmet medical need program director global marketing life edifoligide ef decoy cleveland clinic cycle management focus bristolmyers squibb developing cleveland ohio make plavix part stan corgentech inc biotech dard care patients nology company novel treat experienced arterial thrombotic ment used time surgery events despite use currently seeks help prevent vein graft available agents affect failure following coronary artery underlying disease processes bypass graft surgery peripheral leading events artery bypass surgery still clearly remains significant million patients worldwide unmet medical need undergo vascular bypass surgery dr bhatt also inves tigator plavix clinical trial program says focusing atherothrombosis signif icantimpact fact adds better appreciation biology atherothrombosis may well change practice medicine patients bristolmyers squibb devel oping novel class oral anti thrombotics another weapon clots blood currently phase ii clinical trials lead compound razaxaban novel highly selective factor xa bristolmyers squibb company annual reportf c u b e e iabetes represents treatment type diabetes time bristolmyers immense growing global us years squibb initiated intensive inter medical need million bristolmyers squibb licensed nal research program discover people worldwide suffer glucophage lipha sa develop deliver innovative diabetes complications merck sant sas since new medicines people often include heart disease companys commitment diabetes first product stroke blindness kidney disease diabetes continued grow programmuraglitazar dual limb amputations important medicines like ppar agonistis phase iii narayanan hariharan bristolmyers squibb recog glucophage xr metformin clinical trials muraglitazar targets phd left senior nizedthe critical need medicines extendedrelease tablets two different types ppars principal scientist treat diabetes prevent glucovance glyburide peroxisome proliferatoractivated discovery biology delay onset complications metformin tablets receptors aim man peter cheng phd company launched recently metaglip glipizide aging type diabetes associate director glucophage metformin hailed metformin tablets lipid abnormalities often metabolic diseases first major advance associated especially chemistry high triglyceride low hdl levels annual report bristolmyers squibb companymuraglitazar potentially bristolmyers squibb also first new class compounds licensed inhaled shortacting type diabetes meet broader need people insulin productcurrently results type diabetes says scott phase ifrom qdose joint body produce canterberry vice president venture microdose metabolics global marketing technologies inc quadrant insulin hormone needed muraglitazar global brand drug delivery ltd convert food energy champion really excited diabetes complex type diabetes results potential investi multifaceted disease says fred insulin resistance deficiency gational medicine help people fiedorek md vice president type diabetes clinical design evaluation type diabetes represents percent another promising diabetes exploratory development cases treatmenta novel dpp requires use monotherapy inhibitoris projected enter often multipronged combi phase iii clinical development nation therapy options including physician loyalty established backup compounds glucophage insulinenhancing past decade muraglitazar dpp drugs like ppar agonists betacell soon comprehensive inhibitor earlier stages boosting drugs dpp portfolio products well clinical development inhibitors frequently various able offer weve always complement forms insulin bristolmyers strong really enhance companys current squibb enjoys strong patient ready take diabetes medicines pipeline compounds bristolmyers squibb two scientists one goal entered several important chemist peter cheng phd fight search painstaking licensing pacts among diabetes personal knows month period team synthesized majority people diabetes also suffer screened thousand compounds agreement flamel tech serious cardiovascular risk factors difficult work paid december nologies sa french biopharma dyslipidemia including high triglyceride discovered muraglitazara dual ppar ceuticalcompany develop low hdl levels lead serious agonist single compound would activate heart disease one people father two different ppar receptors ppargamma market basulina controlledrelease wonder dr cheng joined receptor aid glycemic control diabetes longacting unmodified human forces biologist narayanan pparalpha receptor regulate fatty insulin treatment hariharan phd lead team acidlipid metabolism affect cardio bristolmyers squibb scientists vascularrisk phase iii development type type search new inno muraglitazar potential first diabetes basulin vative treatment diabetes important new class drugs currently phase ii generally type diabetes says dr hariharan im enthusiastic cardiovascular risks possibility one medicine helping people clinical development metabolic disorders associated manage diabetes cardiovascular risk treated separately factors adds dr cheng im different medications especially excited muraglitazarfor dr hariharan colleagues dads sake conceptualized single compound could address diabetes dyslipidemia time two set finding single compound bristolmyers squibb company annual reportf c u alzheimers disease estimated currently targeting enzymes development bristol finding new treatments million people industrialized thought generate toxic protein myers squibb treatment obesity therefore easy task countries afflicted may trigger alzheimers chronic hbv infection cur however bristolmyers squibbs alzheimers disease earlier brain two classes compounds rently phase iii trials clini experience expertise related forms unfortunately says gamma secretase beta secretase cal trials conducted far metabolic disorders diabetes amy odonnell md medical inhibitors chemotypes may entecavir shown high efficacy atherosclerosisthrombosis put director neuroscience clinical work halting progression virus says richard company excellent position design evaluation diseaseare currently colonno phd vice president play major role whilebristol aresimply robustly effective investigation companys labs infectious disease drug myers squibbs drug discovery efforts treatments cognition enhancers discovery addition company still early stage company hepatitis currently available dont modify researchers focusing hepa researchers pursuing number progression disease often many million people titis c growing prob promising possibilities significant side effects around world chronically lem currently affects millions focusing two complementary effective diseasemodifying infected hepatitis b virus around world including approaches suppressing appetite agent treatment must clearly hbv many may million americans increasing metabolic rate prevent stop slow progress even know infection large discovery effort rheumatoid dementia thats bristol eventually cause liver cirrhosis liver way focusing multiple targets arthritis myers squibb searching cancer even death fact hbv find viable candidates test thats company ninthleading cause death ing humans rheumatoid arthritis chronic worldwide vaccines help stem progressive autoimmune disorder obesity molecular spread disease body attacks representation treat active hbvinfections much half population human skeleton literally entecavir investigational drug us many indus erodes away joints afflicting leay prevent trializedcountries overweight percent worlds solid organ risk obesity incidence population rheumatoid arthritis transplant obesity rising rapidly devel often results severe longterm rejection opingcountries unfortunately pain disability inflammation current treatments limited experienced terms efficacy tolerability rheumatoid arthritis result safety probably complex disease process triggered multiple wiring loops brain underlying autoimmune make want eat says disorder yet recent therapies simeon taylor md phd vice represent class drugs president discovery biology affecting chemical mediators knock one still inflammation called cytokines lot loops left may bristolmyers squibb recognizes end take one urgent need additional drug see significant lasting treatments rheumatoid effect promotes weight loss arthritis meet challenge company scientists clinical annual report bristolmyers squibb companysolid organ transplantation represents novel mechanism investigators developing organ transplant recipients solid organ transplant rejection action believe may offer abatacept ctlaig novel typically receive cocktail drugs need improve longterm new treatment paradigm approach treat rheumatoid work complementary outcomes organ transplant improving longterm outcomes arthritis mechanism fashion prevent transplanted recipients significant says transplant patients action targets central cause organ viewed foreign richard wright phd vice inflammation joint thus rejected recipients president leay global destruction concept behind immune system time brand champion leay abatacept says mark kreston transplant recipients high vice president abatacept global risk developing comor brand champion inhibit bidities diabetes cardiovascular process inflammation disease kidney toxicity even gets started abatacept leay molecule discovered currently phase iii trials bristolmyers squibb researchers submission regulatory authorities phase ii clinical devel possible near term opment potentially first class drugs called costimu lation blockers prevention back swing things eightyyearold elida francisco suffered rheumatoid arthritis nearly years excruciating pain hands feet stop working couldnt walk couldnt even hold book enrolling clinical trial abatacept ctlaig novel investigational therapy bristolmyers squibb designed shortcircuit process inflammation elida shopping housework important says play grandchildren part family bristolmyers squibb company annual reportf c u n w u n h e r p e u c b ristolmyers squibbs angela diagnosed ulcerative convatec division continually colitis age six time time sharpening focus people ill couldnt attend school depend highestquality life pretty miserable angela ostomy wound therapeutics says couldnt things products services says gary kids could restani president convatec age angela underwent emphasize understanding ileostomy part large intestine customers move forward removed artificial new better products opening created abdomen move ahead elimination bodily waste lives convatec intro since surgery angela says duced six new products life improved dramatically six key initiatives moving getting fitted pouching forward development system challenge though still drawing boards ostomy damaging weve set apart body image angela says competition innovations thats love low profile like aquacel agwound dressings esteem synergyostomy esteem synergyostomy system done wonders system introduced selfimage adds adds nino pionati vice wear system president global marketing formfitting spandex swimsuit research development tight leather pants without worry angela kennedy convatec makes feel confident senior territory manager appearance yorkshire england knows first sales representative hand importance convatec angelas enthusiasm innovations life always product heartfelt go youd never guess counsel fearful ostomy patients see hear gives lot reassur easy sell anceand confidence says angela product like esteem synergysystem esteem synergy really brilliant theres way im believe going back rely upon says angela kennedy convatec senior territory manager annual report bristolmyers squibb companyi n f n n c h l n u r n global organization recently mead johnson metabolic disorders reflects care effective products regular often judged well developed new disorder exacting attention company feeding rare serves needs specific products many gives brand challenging cases camilles specialized customers available us name products available keep eye whats really take monthold camille countries france first countries mead johnson importantour customers sanchez salon france shes country launched excellent first choice feeding perfect baby mom readily entire range since diagnosis infants breastfed proclaims camille indeed msud days age says kim carpenter director camille delightful child runs camille followed strict diet global marketing coordination adorable little climbs everywhere naturally includes two products precisely girl says mom sanchez family grateful camille first mead johnson bcad demonstrated medical leads normal exuberantly healthy infants bcad technical expertise develop life thanks youd never know best chance help babies begin mead johnson camille suffers rare life continuous treatment threatening metabolic disorder right formula immediately called maple syrup urine disease birth says aiphi nguyen msud camille metabolic line manager mead affected children consequences johnson france devastating infants mead johnsons continued msud unable metabolize commitment relatively small break certain amino acids number families dealing build toxic levels possibly lead mental retardation coma even death fortunately children lead healthy lives theyre diagnosed earlyand treated proteinrestricted diet entire lives mead johnson world leader infant child nutrition enfamil enfalacand well known brands supported general special feeding needs babies almost century nearly years mead johnson pioneered metabolic products help infants like camille grow healthily adulthood bristolmyers squibb company annual reportf c u c l r e p n b l waziland southern african seeks address serious health makes initiative established grants totaling kingdom nestled south social threat innovative unique reaches million bristolmyers africa mozambique may comprehensive way new whole family unitto mother squibb announced end small sizea little larger clinic swazi capital partner childthrough sites part connecticutbut saddled mbabane opened treatment well followup companys pioneering million enormous burden hivpositive women support communities commitment provide support onethird adult newborns go receive inex wherethese people live says women children infected inhabitants defined men pensive antiretroviral therapy busi bhembe director affected hivaids women aged believed therapy includes medicine help swaziland infant nutrition action nine countries southern hiv positiveamong prevent mothertochild transmis network local nongovernmental western africa crisis many pregnant women sion hiv well organization managing especially acute danger passing virus extensive treatments initiative counselors new projectsincluding newborns apart health advanced disease volunteers help mothers one swazilanddraw challenges many addition womens male partners find buddies key learnings four years hivaids face discrimination partners receive education supportive individuals work secure isolation difficulties hivaids necessary communities work future says john l damonti trying live lives treatment newborn children ensure eating president bristolmyers squibb new project funded monitored determine properly adhering treat foundation focusing bristolmyers squibb part hiv status provided ment regimens receiving integrating medical services companys secure therapy appropriate following medical psychological care enhanced communitybased care future initiative fight treatment people says support address broad hivaids subsaharan africa access wide range swaziland project one range challenges posed enhanced cases six new secure future hivaids goal demon new community support services community treatment sites strate document approach replicated resourcelimited settings thinking regionally acting locally reversing tide hivaids africa four years since bristolmyers squibb support medical research care well launched pioneering secure community outreach education futureinitiative fight hivaids programs women children subsaharan africa death toll countries cases disease topped staggering million infection rates exceed one people still great deal changed every three adults approach time potentially help stem tide partner local organizations disease future says john l mcgoldrick find solutions resourcelimited executive vice president general counsel settings build local health bristolmyers squibb prevention strategies care social services capacity showing results new institutions says mr mcgoldrick approaches taking root region successful must take fight address medical well social hivaids directly economic needs people living homes schools clinics communities hivaids consequences says people affected terrible secure futuregrantswhich pandemic totaled almost million end annual report bristolmyers squibb companyin swaziland community mothersand hope many educators begun fanning male partners children region surrounding says clear project mbabane spread word giving many people back hope clinic followup future people program according ms bhembe hiv medicines represent response enthusiastic important lifeline good start caring community enrolling target number resources knowledge help live full productive meaningful lives bristolmyers squibb company annual reportf c u e x e n n g n e n h n c n g l f e n bristolmyers squibb three bristolmyers squibb patients worldwide defeat cancer conquer aids teamed cancer survivor cancer medications indiana companys trials fight diabetes extend fivetime tour de france champion university cancer centerlance recognized models enhance human life ultimately lance armstrong sponsor said count among entire pharmaceutical industry hope goal bristolmyers squibb tour millions people owe biomedical research represents upon bristolmyers squibb ofhope unprecedented lives advances cancer therapy currency hopefor focused week long coasttocoast cycling made clinical trials children future eventfrom los angeles todays clinical trials washington dc discovering tomorrows medical october tourof breakthroughs bristol hope team cancer survivors myers squibb supported caregivers physicians nurses clinical trials involving researchers began mile odyssey en route team delivered messages hope cancer survivors patients family members gathering indianapolis lance treated testicular cancer lance armstrong cancer survivor jackson verbanic age tour hope finale washington dc annual report bristolmyers squibb companyfinancial review managements discussion analysis consolidated financial statements notes consolidated financial statements report management independent accountants fiveyear financial summary managements discussion analysis financial condition results operations managements discussion analysis financial condition results matters affecting company reasonably likely material operations revised reflect restatement companys results operations cash flows may material financial condition liquidity additional discussion matter see summary note legal proceedings contingencies company reported annual global sales billion sales longterm debt increased billion december increased prior year level reflecting volume increases net billion december primarily due billion fixed rate notes price increases impact foreign exchange fluctuations billion floating rate convertible debentures issued august us sales increased partly due impact sales october respectively proceeds issuances used workdown nonconsignment wholesaler inventory international sales repay shortterm borrowings fund cash needs us operations increased including favorable foreign exchange impact cash provided operating activities billion working company two product lines sales billion capital billion december company paid dividends pravacholand plavix pravacholsales grew including favorable approximately billion provided dividend yield eign exchange impact billion plavix sales grew including consistent companys mission extend enhance favorable foreign exchange impact billion addition two human life developing highestquality products company invested products company product lines million billion research development growth research annual sales including product lines million development dedicated pharmaceutical products including milestone pay annual sales six annual sales excess million ments inlicensing development programs billion per earnings continuing operations minority interest income centage pharmaceutical sales compared taxes increased million million compound annualized growth pharmaceutical research development net earnings continuing operations million spending past five years per share basic diluted basis respectively compared restatement previously issued million per share basic diluted basis respectively financial statements company expects exclusivity losses new product mix challenge margins company remains committed investing busi company restating consolidated balance sheet december nesses maximize key growth drivers advance pipeline several items consolidated statements earnings cash flows comprehensive affected comparability results discussed income retained earnings years ended december earnings outlook financial statements first second third quarters december company held almost billion cash cash including comparable interim periods restatement equivalents marketable securities approximately billion cash restatement affects periods prior impact restatement cash equivalents marketable securities held companys foreign prior periods reflected adjustment opening retained earnings subsidiaries company expect repatriate foreseeable january restatement reported annual report future company expects cash generated us operations annual report year ended december together borrowings capital markets sufficiently cover cash reported amendments quarterly reports form q quarterly needs working capital capital expenditures dividends us periods ended march june september repatriation united states would require additional tax provisions restatement corrects certain company 's historical accounting reflected consolidated financial statements discussion policies conform us generally accepted accounting principles gaap matter see critical accounting policiesincome taxes ii corrects certain errors made application gaap company subsidiaries subject number significant late october company determined certain sales pending lawsuits claims proceedings investigations possible certain wholesalers us pharmaceuticals business accounted time reasonably assess final outcome investigations litigations consignment sales accounting model accordingly determined management continues believe previously disclosed next restate sales earnings sales wholesalers following years aggregate impact beyond current reserves legal determination company also determined would correct certain bristolmyers squibb company annual reportiiiiihistorical accounting policies conform accounting gaap certain ended december pwc advised company audit known errors made application gaap previously committee reportable condition income tax accounting area recorded case company believed amount remains company expects complete remediation reportable error material company 's consolidated financial statements condition end addition part restatement process company investigated throughout managements discussion analysis financial condition accounting practices certain areas involve significant judgments result operations referenced amounts prior periods prior determined restate additional items respect company con period comparisons reflect balances amounts restated basis cluded errors made application gaap including certain revisions net sales inappropriate accounting march company completed restatement financial statements items restated financial sales billion increase prior year statements three years ended december including corre increase sales driven volume increased levels sponding interim periods first second quarters including partly due impact sales workdown nonconsignment comparable prior interim periods restatement wholesaler inventory us sales increased million compared completing restatement company continued identify decrease million international sales increased implement actions improve effectiveness disclosure controls million including favorable foreign exchange procedures internal controls financial reporting connection impact compared increase million signifi effort company substantially strengthened organization cantforeign exchange impact general companys business seasonal personnel senior financial control functions ii adopted rigor information us pharmaceuticals prescriber demand reference made ous policies procedures respect balance sheet review process iii table within business segments pharmaceuticals section focused internal audit function financial reporting controls iv engaged sets forth comparison changes net sales estimated total prescrip consultant assist evaluation documentation certain financial tiongrowth retail mail order customers certain companys reporting disclosure processes throughout company v engaged primary care pharmaceutical products sales billion compared consultant assist comprehensive detailed review certain billion increase sales included companys tax reporting accounting addition request approximately million million respectively sales related companys audit committee companys independent auditors performed products acquired part dupont pharmaceuticals acquisition dupont extensive procedures respect companys interim financial pharmaceuticals completed october domestic sales information based auditors assessment companys decreased million international sales increased risk profile expanded scope amount field work performed million foreign exchange significant impact certain areas connection audit company actions composition net increase sales follows contributed significantly company identifying additional errors relating restated prior periods reflected restatement discussion individual restatement adjustments see note restatement previously volume issued financial statements years ended december selling prices net connection audits restatement companys foreign exchange consolidated financial statements year ended december increase sales companys independent auditors pricewaterhousecoopers llp pwc identified communicated company audit committee two material weaknesses defined standards established american significant portion companys us pharmaceuticals sales made institute certified public accountants aicpa relating companys wholesalers company experienced substantial buildup wholesaler accounting public financial reporting significant matters initial inventories us pharmaceuticals business several years primarily recording management review oversight certain accounting matters buildup primarily due sales incentives offered addition time pwc identified communicated company company wholesalers including discounts buyins anticipation audit committee reportable condition defined standards price increases extended payment terms certain us pharmaceuticals established aicpa relating companys internal controls wholesalers generally offered toward end quarter financial reporting income taxes company dedicated substantial incentive wholesalers purchase products amount sufficient meet resources improving controls accounting financial disclosure companys quarterly sales projections established companys senior reporting auditors identified material weaknesses con management timing companys recognition revenue sales nection audit financial statements addition company wholesalers differs wholesaler period devoted substantial resources towards remedying reportable condition historically company recognized revenue sales upon shipment relation taxes company also retained consultant assist compre products customers gaap revenue recognized substan hensive detailed review certain aspects tax accounting report tially risks rewards ownership transferred case sales ing company examined financial reporting taxes significant made wholesalers result incentives ii excess wholesalers jurisdiction company one subsidiaries subject tax ordinary course business inventory level iii time result review number prior period errors identified understanding agreement course dealing consistent business practice reflected restatement addition company undertook company would extend incentives based levels excess inventory review evaluate certain issues raised concerning manner connection future purchases iv time incentives would company determined provision income taxes company cover substantially vary directly wholesalers cost carrying determined prior certain inappropriate adjustments inventory excess wholesalers ordinary course business inventory tax contingency reserves made improper purpose recording provi level substantially risks rewards ownership transfer upon sion income taxes consistent companys projected effective tax rate shipment accordingly sales accounted using con addition may inappropriate adjustments signment model determination sales wholesaler meet company completed review able determine foregoing criteria involves evaluation variety factors number whether errors relating tax contingency reserves complex judgments corrected restatement related inappropriate accounting connection situations described utilizing consignment model audit companys consolidated financial statements year company recognize revenue upon shipment product rather upon iiiii annual report bristolmyers squibb companyshipment product company invoices wholesaler records deferred rev continuing operations increased enue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company years ended december company recognizes revenue net discounts rebates estimated sales allowances accruals recorded several items affected comparability results periods returns consignment inventory longer subject incentive presented herein set forth following table discussion arrangements later inventory sold items see note alliances investments note restructuring wholesalers customers firstin firstout fifo basis additional discussion items note acquisitions divestitures note discontinued companys revenue recognition policy see note accounting policies operations restatement company restated previously issued finan cial statements period second quarter cor restated restated rect timing revenue recognition certain previously recognized us dollars millions pharmaceuticals sales cardinal health inc cardinal mckesson acquired inprocess research development corporation mckesson two largest wholesalers companys us litigation charge net pharmaceuticals business based application criteria asset impairment charge recorded error time shipment accounted investment imclone using consignment model restructuring items december companys aggregate cost phar gain sales businessesproduct lines maceutical products held cardinal mckesson accounted using consignment model accordingly reflected consignment income tax benefit items inventory companys consolidated balance sheet approximately settlement prior year tax matters million million respectively approximately million million december respectively related oncology prod ucts sold oncology therapeutics network otn deferred restructuring items consist following revenue recorded gross invoice sales price related inventory phar maceutical products accounted using consignment model approxi cost provision mately million million december products restructuring respectively approximately million million december dollars millions sold rd total respectively related otn result restatement application consignment model approximately million year ended december sales excluding otn net discounts rebates adjustments upfront payments reversed period approximately four licensing agreements million million recognized revenue accelerated depreciation assets respectively consigned inventory held cardinal mckesson termination benefits worked significant portion workdown recognized exit costs first quarter corresponding effect earnings continuing opera relocation expenses tions minority interest income taxes increase million asset impairment million respectively sales cardinal retention benefits mckesson represented approximately us change estimates pharmaceuticals net sales respectively company estimates based data noted inventory pharmaceutical products held us pharmaceuticals wholesalers cost provision range approximately million excess approximately products restructuring dollars millions sold rd total one month supply december estimate subject inherent limitations estimates rely thirdparty data certain thirdparty infor year ended december mation form estimates reflect limitations termination benefits company expects account certain pharmaceutical sales relating otn exit costs using consignment model agreement mckesson expires accelerated depreciation assets earnings asset writedown impairment charges earnings continuing operations minority interest change estimates income taxes increased million million increase primarily result sales increase specified charges million recorded litigation settlements asset impairments decrease cost provision writeoffs inprocess research development increase par net products restructuring tially offset increased investment advertising promotion mar dollars millions sales sold total keting selling administrative expenses earnings continuing operations increased million million year ended december basic diluted earnings per share continuing operations increased downsized rationalized respectively operations facilities respectively earnings continuing operations minority abandonment nonstrategic interest income taxes increased million million pharmaceutical product lines earnings continuing operations increased change estimates million million basic diluted earnings per share continuing operations increased respectively respectively net earnings margins bristolmyers squibb company annual reportiiiiigross margin percentages states percentage sales advertising promotion expenses respectively gross margins negatively impacted due increased increased sales lowermargin products otn segment million companys investment research development totaled mil accelerated depreciation charges million charge asset impairment lion increase increase restructuring expenses largely offset increased sales higher mar percentage sales decreased compared gin products pravachol lower gross margin compared research development costs included principally due impact generic competition united million charges related upfront payments licensing agreements states glucophage ir taxol buspar adverse change prod million accelerated depreciation research facilities uct mix due increased sales otn segment research development spending dedicated pharmaceutical effective income tax rate earnings continuing operations products decreased pharmaceuticals sales compared minority interest income taxes compared respectively company focusing increase effective tax rate research development activities fully realize value effective tax rate primarily due decrease effective tax rate benefit research development pipeline new priorities include rebalancing drug operations ireland puerto rico switzerland treatment provisions discovery development increase support companys full latestage certain litigation reserves nondeductible increase estimates development pipeline closing unnecessary facilities also include contingent tax matters compared increase devoting greater resources ensuring successful nearterm product launches effective tax rate effective tax rate primarily due decrease increasing companys efforts inlicensing opportunities effective tax rate benefit operations ireland puerto rico switzerland charges related acquired inprocess research development provision million valuation allowances comprised million primarily related milestone payments imclone systems million related certain state foreign net deferred tax assets million incorporated imclone erbitux million milestone payment related certain state foreign tax net operating loss tax credit carryfor imclone million expensed acquired inprocess research wards partially offset million net release tax contingency reserves development first quarter remaining million recorded related primarily settlement prior year tax matters determination additional equity investment eliminate income statement effect company expected settlement ongoing tax litigation portion milestone payment company economic resolved company currently believes state net deferred claim ownership interest imclone acquired inprocess research tax assets state net operating loss tax credit carryforwards foreign net development charge million including million operating loss tax credit carryforwards valuation allowances related dupont pharmaceuticals acquisition million attributable provided likely realized future lower imclone equity investment addition acquired inprocess research effective income tax rate results primarily lower pretax income development includes charges million million united states due writeoff acquired inprocess research devel respectively licensing payments related products yet approved marketing opment well proportionately greater tax benefits income earned restructuring programs implemented downsize realign stream lower tax rate jurisdictions ireland puerto rico switzerland line operations order increase productivity reduce operating expenses rationalize companys manufacturing network research facilities expenses administrative functions actions restructuring program total costs expenses percentage sales com expected complete actions pared restructuring programs substantially complete december cost products sold percentage sales increased last three result actions company expects future annual benefit years compared earnings continuing operations minority interest income taxes principally due increased sales lowermargin products otn largely approximately million million million offset increased sales higher margin products pravachol programs respectively additional information restruc cost products sold includes million accelerated depreciation assets turing see note restructuring items manufacturing facilities north america expected closed end litigation charges net settlement income million million charge asset impairment restructuring compared million million fourth quar expenses cost products sold included million reversal prior ter company established reserves liabilities total amount period reserves inventory writeoffs related cancelled actions million comprised million relation wholesaler inventory included million restructuring expenses issues certain accounting matters million relation marketing selling administrative expenses percentage sales pharmaceutical pricing sales marketing practices addition decreased marketing selling company recorded charges million litigation matters administrative expenses increased million mil recognized income million million income consists primarily lion primarily due increased sales support abilify million income patent defense cost reimbursement million avaproavalide higher pension costs higher charges related system infra litigation settlement income million settlement antitrust structure higher insurance premiums unfavorable foreign exchange litigation involving vitamin manufacturers charges million impact principally related euro marketing selling administrative primarily related busparand taxolproposed settlements additional expenses percentage sales increased information litigation see note legal proceedings contingencies million million slight increase equity net income affiliates million compared mainly due higher sales force expenses result addition million million respectively equity net medical imaging business acquired october income affiliates principally related companys joint venture advertising promotion expenses increased million sanofisynthlabo sanofi investment imclone increase million primarily result promotional support equity net income affiliates primarily reflects higher net income abilify reyataz launches plavix united states additional sanofi joint venture additional information equity net income support inline products unfavorable foreign exchange impact affiliates see note alliances investments europe advertising promotion expenses decreased mil expenses net income million million mil lion million primarily result reduced spending lion respectively expenses include net interest metformin franchise vaniqa partially offset abilify product launch expense interest income foreign exchange gains losses royalty income expenses increased support plavix avaproavalide united gains losses disposal property plant equipment decrease iiiii annual report bristolmyers squibb companyexpenses primarily due net gains interest rate including favorable foreign exchange impact million sales swaps increase expenses compared principally due pravacholfranchise increased million higher interest expenses related borrowings billion related million sixmonth exclusivity extension granted dupont pharmaceuticals imclone transactions april sales plavix platelet aggregation inhibitor increased including business segments favorable foreign exchange impact million sales company operates four reportable segmentspharmaceuticals avaproavalide angiotensin ii receptor blocker treatment otn nutritionals healthcare otn previ hypertension increased including favorable foreign exchange ously included pharmaceuticals segment met quantitative thresholds impact million sales plavix avaproavalide increased reportable segment outlined sfas disclosure segments million million respectively enterprise related information accordingly prior periods sales plavix avaproavalide million million reclassified conform current year presentations percent plavix avaproavalide cardiovascular products companys sales segment follows launched alliance bristolmyers squibb sanofi total sales sales taxol paraplatin companys leading anticancer agents restated restated increased including favorable foreign exchange impact million million significant foreign exchange impact respectively international sales taxol increased pharmaceuticals including favorable foreign exchange impact million led oncology therapeutics network strong sales japan france domestic sales taxol decreased nutritionals million due generic competition domestic sales paraplatin healthcare increased million taxol sales decreased million million paraplatinsales increased pharmaceuticals million million worldwide pharmaceuticals sales increased million sales sustiva antiretroviral agent treatment human immuno reflecting price increase volume increase increase foreign deficiency virusacquired immunodeficiency syndrome hivaids increased exchange domestic sales increased million primarily including favorable foreign exchange impact million due increased sales plavix pravacholfranchise abilify total revenue million prior year international sales sustivaincreased glucovance paraplatin partly due impact sales including favorable foreign exchange impact million workdown nonconsignment wholesaler inventory partially offset sustivawas acquired dupont pharmaceuticals october decreased sales glucophage ir taxol primarily due generic compe recorded sales million year tition reyatazwas launched july million domestic sales monopril secondgeneration angiotensin converting enzyme ace international sales increased million including inhibitor treatment hypertension increased sales favorable foreign exchange impact primarily due increased sales pravachol including favorable foreign exchange impact reaching million taxol plavix avaproavalide analgesic products europe partially monopril sales increased million mil offset price declines principally germany italy lion worldwide pharmaceuticals sales decreased million glucophage franchise sales increased million com reflecting price decline volume decline foreign exchange pared decrease million million impactdomestic sales declined million primarily due glucophage ir oral medication treatment noninsulin generic competition united states glucophage ir taxol dependent type diabetes saw sales decrease million buspar partially offset increased sales plavix addition products decline glucophage ir due introduction generic met acquired dupont pharmaceuticals acquisition completed formin united states early glucophage ir sales decreased october addition decrease domestic pharmaceutical sales million million glucovance impacted buildup prior period inventory levels us oral combination drug glucophage xr extended release tablets wholesalers accounted consignment model subsequent sales million million respectively compared workdown approximately million sales calculated net sales million million respectively sales discounts rebates adjustments recognized year ended million million respectively december reversed prior years international sales increased sales zerit antiretroviral agent used treatment hivaids millionwith significant foreign exchange impact primarily decreased including favorable foreign exchange impact due increased sales pravacholand plavix europe taxol japan million primarily result decreased demand due potential addition products acquired dupont pharmaceuticals acquisition adverse side effects zeritsales decreased million key pharmaceutical products sales include following million total revenue abilify primarily domestic alliance revenue sales videxvidexec antiretroviral agent used treatment companys share net sales copromotion countries otsuka hivaids increased including favorable foreign exchange pharmaceutical co ltd otsuka million schizophrenia impact million videxvidexec sales increased agent introduced united states november million million december achieved weekly new prescription share sales serzone treatment depression decreased million us antipsychotic market company received approval result loss exclusivity labeling change indicating poten supplemental new drug application snda abilify maintaining sta tial serious side effect product serzonesales decreased bility patients schizophrenia announced submitted million million snda abilify treatment acute mania patients bipolar disorder us food drug administration fda abilify following table sets forth comparison reported net sales changes developed marketed bristolmyers squibb partner otsuka estimated total prescription growth retail mail order cus sales pravacholfranchise increased including favorable tomers certain companys us pharmaceutical prescription prod eign exchange impact million domestic sales increased ucts estimated prescription growth amounts based thirdparty data million international sales increased provided ims health supplier market research pharmaceutical bristolmyers squibb company annual reportiiiiiindustry significant portion companys domestic pharmaceutical sales billion reflecting increase due price offset decrease due made wholesalers changes reported net sales differ prescrip volume decrease due foreign exchange worldwide infant formula tion growth change net sales may reflect underlying prescriber demand sales decreased million primarily specialty infant formula business worldwide sales enfamildecreased million million worldwide childrens nutritional sales increased restated restated including unfavorable foreign exchange impact million change change change change change change million result increase sales us ustotal us us total us ustotal enfagrow primarily across pacific region million net sales prescriptions net sales prescriptions net sales prescriptions b b b earnings minority interest income taxes nutritionals segment increased million million increase pravachol primarily due increased sales enfamilin united states earnings plavix minority interest income taxes nutritionals segment decreased avaproavalide million million result increased promotional sustiva na spending sales force expenses related enfamilproduct line monopril glucovance healthcare glucophage xr healthcare segment includes convatec medical imaging zerit business consumer medicines united states japan cefzil sales healthcare segment increased million coumadin na million healthcare sales increase videxvidexec result increase due volume increase changes selling prices excess increase due foreign exchange sales segment increased reflects change net sales dollar terms including change average selling prices whole million including million sales medical imaging saler buying patterns purchased october part dupont pharmaceuticals b reflects change total prescriptions unit terms based thirdparty data acquisition healthcare sales increase result increase due volume increase changes selling prices earnings minority interest income taxes million favorable foreign exchange impact healthcare sales business increased million primarily due increased sales follows partially offset increased advertising product spending change new existing inline products earnings minority interest income taxes million million respectively restated restated increase mainly due lower earnings result dollars millions writeoff million acquired inprocess research development earnings unfavorably affected higher sales lower margin convatec products full year impact generic competition glucophage ir medical imaging taxol busparin united states consumer medicines total healthcare oncology therapeutics network excess otn sales million increase prior year due volume growth manufacturers price changes sales increased million million otn sales increase convatec sales due increase including accounted companys net sales favorable foreign exchange impact worldwide sales ostomy products respectively million strong growth worldwide wound care products earnings minority interest income taxes million increased including favorable foreign exchange impact mil decreased slightly million million due lion foreign exchange favorable effect sales margin erosion investments system infrastructure increase convatec sales due increase worldwide sales ostomy products million strong growth worldwide wound care nutritionals products increased million foreign exchange contributed nutritionals sales million increase sales increase increase due increase volume price increase increase medical imaging sales increase partially offset decrease due foreign exchange international sales volume increase changes selling prices increase due increased including unfavorable foreign exchange impact foreign exchange worldwide sales cardioliteincreased million million million domestic sales increased million medical imaging business purchased million million worldwide childrens nutritionals sales october part dupont pharmaceuticals acquisition increased including unfavorable foreign exchange impact steady decline sales consumer medicines million million million result increase sales million million part due distributors enfagrow primarily throughout pacific region million reducing inventory levels desirable levels consumption excedrin worldwide infant formula sales increased million consumer brands remain flat significant foreign exchange impact primarily due increased sales earnings minority interest income taxes healthcare enfamil companys largestselling infant formula international sales segment decreased million million primarily enfamilincreased million million result unfavorable product mix inventory writeoffs excedrin significant foreign exchange impact domestic sales enfamilincreased quicktabs consumer medicines business earnings million million mead johnson minority interest income taxes segment increased million nutritionals mead johnson continues leader us infant million primarily due strong growth convatec mula market nutritionals sales remained consistent sales business addition medical imaging business october iiiii annual report bristolmyers squibb companygeographic areas december company confirmed mead johnson wholly companys products available virtually every country world owned subsidiary company reached agreement novartis ag largest markets united states france japan germany spain novartis sell novartis adult nutritional business brands trademarks italy canada patents intellectual property rights million including million sales united states increased primarily due increased contingent product conversion million upfront payment sales plavix otn segment pravacholfranchise abilify total revenue supply agreement transaction closed february pretax gain glucovance paraplatin sales increases partially offset approximately million expected recorded first quarter continued impact generic competition united states glucophage ir adult nutritional products recorded sales million taxol result loss exclusivity label change indicating december company lexicon genetics incorporated potential serious side effect serzone sales united states decreased lexicon formed broad alliance drug discovery development com primarily due impact generic competition united states mercialization neuroscience field alliance designed accelerate glucophage ir taxol busparand lesser extent buildup discovery development breakthrough therapies address significant prior period inventory levels us wholesalers accounted unmet medical needs psychiatry neurology company made consignment model subsequent workdown decrease expensed initial payment million partially offset increase plavix sales addition products october company corgentech inc biotechnology com acquired dupont dupont pharmaceuticals us pharmaceuticals sales pany entered agreement jointly develop commercialize million companys acquisition dupont pharmaceuticals corgentechs ef decoy edifoligide treatment prevention vein completed october information us pharmaceuticals graft failure following coronary artery bypass graft peripheral artery bypass prescriber demandrefer table within business segments graft surgery product currently phase iii clinical trials fda pharmaceutical segment sets forth comparison changes net sales granted fast track status indications company made estimated total prescription growth retail mail order cus expensed initial payment million potential tomers certain companys primary care pharmaceutical products clinical regulatory milestone payments million arrangements sales europe middle east africa increased including profit sharing increase foreign exchange result sales growth pravacholin france august pravigard pac buffered aspirin pravastatin taxol france germany spain italy analgesics france plavix sodium tablets launched united states germany spain avaproavalide italy sustivain spain favorable july reyataz protease inhibitor treatment hivaids impact foreign exchange primarily due euro sales europe launched united states march company received middle east africa increased including increase foreign marketing approval reyatazin eu exchange result strong growth pravacholin france united august company entered licensing commercializa kingdom plavix spain addition dupont pharmaceuticals tion agreement flamel technologies sa develop market basulin products several markets region dupont pharmaceuticals sales first controlled release unmodified human insulin developed region million oncedaily injection patients type type diabetes basulinis sales western hemisphere countries increased including entering phase ii clinical development agreement company decrease foreign exchange primarily due increased sales plavix lead assume cost future development manufacturing efforts canada unfavorable impact foreign exchange primarily mexico basulinand exclusive worldwide rights product company brazil venezuela sales western hemisphere countries made expensed initial payment million october decreased including decrease foreign exchange unfavor potential additional million clinical regulatory milestone able impact foreign exchange primarily brazil argentina payments time royalty payments product sales underlying sales growth primarily due increased sales plavix canada financial position liquidity nutritional products mexico capital resources pacific region sales increased including increase foreign exchange result increased sales taxol japan cash cash equivalents marketable securities totaled approximately increased sales enfagrowthroughout region sales pacific billion december compared billion december region increased including decrease foreign exchange products approximately billion cash cash equivalents marketable securities strong growth included taxol paraplatinin japan nutritional held companys foreign subsidiaries company products china indonesia expect repatriate foreseeable future company expects cash generated us operations together borrowings capital developments markets sufficiently cover cash needs working capital capital expenditures february fda approved biologics license application dividends us repatriation united states would require addi bla erbitux anticancer agent company developing tional tax provisions reflected consolidated financial statements partnership imclone erbitux injection use combination discussion matter see critical accounting policiesincome irinotecan treatment patients epidermal growth factor receptor taxes working capital increased billion december egfrexpressing metastatic colorectal cancer refractory irinote billion december primarily result increase canbased chemotherapy use single agent treatment marketable securities decrease commercial paper outstanding partially patients egfrexpressing metastatic colorectal cancer intolerant offset increased accrued expenses cash cash equivalents marketable irinotecanbased chemotherapy accordance agreement securities conversion workingcapital items borrowings company paid imclone million march milestone payment expected fund nearterm operations approval erbitux fda cash cash equivalents december primarily consisted us january company announced agreed acquire dollar denominated bank deposits original maturity three months acordis specialty fibres acordis privately held company based united less marketable securities december primarily consisted us kingdom licenses patent rights supplies materials convatec dollar denominated floating rate instruments aaaaaa credit rating wound therapeutics line transaction subject regulatory approval due nature instruments company considers reasonable received transaction completed company expect fair market values significantly impacted expects record inprocess research development charge change interest rates liquidated cash short notice million million average interest yield cash cash equivalents bristolmyers squibb company annual reportiiiiidecember respectively interest yields marketable dividends declared per common share years securities averaged respectively december company declared longterm debt december denominated primarily us quarterly dividend per common share indicated dividend dollars also included japanese yen longterm debt million long full year per share term debt increased billion december billion companys financial condition liquidity could affected obliga december primarily due billion fixed rate notes tions make milestone onetime payments outcome billion floating rate convertible debentures issued august pending litigations investigations including challenge plavix october respectively proceeds issuances used patent information see note alliances investments note repay shortterm borrowings fund cash needs us operations legal proceedings contingencies convertible debentures mature callable par time contractual obligations september issuer convertible company com mon stock shares per debenture per share subject payments due period companys contractual obligations increases maximum shares per debenture based december follows increases market price stock per share plus antidilu obligations expiring period tion certain adjustments interest payable quarterly annual later rate equal month libor reset quarterly minus majority dollars millions total years companys debt fixed rate company however entered fixed shortterm floating interest rate swaps billion longterm debt interest borrowings expense million million longterm debt million respectively us commercial paper outstanding capital leases december us commercial paper outstanding december operating leases million average interest rate average interest purchase obligations rate year ended december international short imclone milestone term borrowings respectively current install payment ments longterm debt respectively standby letters december company two revolving credit facilities credit totaling billion aggregate support domestic commercial paper longterm program facilities established september august liabilities respectively syndicate lenders extendable anniversary total date consent lenders one revolving credit facilities certain financial covenants company compliance obligations included shortterm borrowings companys consolidated balance december borrowings outstanding revolving sheet december balances represent outstanding nominal longterm debt values credit facilities december company unused shortterm lines credit foreign banks million million addition company committed make potential december respectively future milestone payments thirdparties part inlicensing develop july standard poors lowered longterm credit rating ment programs payments agreements generally become due company aa aa addition standard poors affirmed payable upon achievement certain developmental regulatory andor shortterm rating april moodys investors service lowered commercial milestones achievement milestones neither companys longterm credit rating aa march moodys probable reasonably estimable contingencies recorded affirmed prime shortterm credit rating company march companys consolidated balance sheet standard poors placed longterm shortterm ratings discussion contractual obligations reference made note company watch negative implications moodys longterm credit rating shortterm borrowings longterm debt note financial instruments remains negative outlook note leases note pension postretirement benefit plans net cash provided operating activities approximately billion offbalance sheet arrangements billion billion increase attributable higher net earnings income tax payments primarily march company imclone revised agreement related gain arising sale clairol business cash flow reducing total payment million billion pursuant operations also included pension contributions million million agreement company paid imclone million million million respectively million accordance agreement company cash provided operations borrowings primarily used paid imclone million march milestone payment past three years pay dividends billion repurchase million approval erbitux fda pay additional million shares cost billion company also erbitux approved use second tumor type discussion invested billion past three years capital expansion improve companys agreement imclone see note alliances investments plant efficiency maintain superior research facilities recently issued company purchase common stock accounting standards company repurchased million million shares common stock cost million million respectively bring january financial accounting standards board fasb issued ing total shares acquired since share repurchase programs inception staff position fas accounting disclosure requirements related million shares share repurchase program authorizes company medicare prescription drug improvement modernization act purchase common stock time time open market pri act act introduces prescription drug benefit medicare vate transactions market conditions permit program intended well federal subsidy sponsors retiree health care benefit plans pro reduce increase shares outstanding option exercises obtain vide benefit least actuarially equivalent medicare part pres shares general corporate purposes ent detailed regulations necessary implement act including employment levels december remained constant account federal subsidy issued company elected compared prioryear levels iiiii annual report bristolmyers squibb companyto defer recognizing effects act authoritative guidance december fasb issued sfas accounting stock accounting federal subsidy issued based compensationtransition disclosure sfas amends sfas december staff securities exchange commission accounting stockbased compensation provide alternative methods sec issued staff accounting bulletin sab revenue transition voluntary change fair value based method accounting recognition supersedes sab revenue recognition financial stockbased employee compensation addition sfas amends statements sab primary purpose rescind accounting guidance con disclosure requirements sfas require prominent disclosures tained sab related multiple element revenue arrangements super annual interim financial statements method accounting seded result issuance eitf accounting revenue stockbased employee compensation effect method used arrangements multiple deliverables additionally sab rescinds reported results provisions sfas effective financial state secs revenue recognition financial statements frequently asked questions ments year ended december sfas answersthe faq issued sab codified sec material impact companys consolidated financial statements topic revenue recognition wording sab changed adoption standard require company change reflect issuance eitf revenue recognition principles sab company plan change fair value based method accounting remain largely unchanged issuance sab initial adoption stockbased compensation accounting pronouncement material effect november fasb issued fin fin requires guarantor companys consolidated financial statements recognize liability inception guarantee fair value december fasb amended statement financial accounting obligation undertaken issuing guarantee include detailed disclo standards sfas employers disclosures pensions post sure respect guarantees types contracts company enters retirement benefits amended statement revises employers disclosures meet scope interpretation financial performance standby pension plans postretirement benefit plans change letters credit behalf wholly owned subsidiaries fin effective measurement recognition plans required fasb statements guarantees issued modified december initial adoption employers accounting pensions employers accounting settlements accounting pronouncement material effect companys curtailments defined benefit pension plans termination benefits consolidated financial statements employers disclosures postretirements plans pensions retirement benefits revisions included amended statement effective financial state ments fiscal years ended december company plan description provided required disclosures see note pension postretirement company certain subsidiaries defined benefit pension benefit plans note legal proceedings contingencies plans defined contribution plans regular fulltime employees prin december fasb revised interpretation consolidation cipal defined benefit pension plan bristolmyers squibb retirement variable interest entitiesfin fin requires variable interest entity income plan principal defined contribution plan bristolmyers consolidated company company subject majority risk squibb savings investment program loss variable interest entitys activities entitled receive majority approximately total company defined benefit pension plan assets entitys residual returns fin also requires disclosures liabilities held us plans assets us plans held variable interest entities company required consolidate single trust common asset allocation unless specified otherwise ref whichit significant variable interest consolidation requirements erences section total company plans us plans together fin revised apply immediately variable interest entities created international plans january existing entities first fiscal year interim period benefits companys defined benefit pension plans based primarily beginning march certain disclosure requirements apply years credited service participants compensation assets financial statements issued january regardless variable companys defined benefit plans consist primarily equity fixedincome interest entity established initial adoption accounting pronounce securities december fair market value plan assets mentdid material effect consolidated financial statements companys defined benefit plans increased million million may fasb issued sfas accounting certain financial december us plans assets allocated equity instruments characteristics liabilities equity sfas securities compared end fixed income securities establishes standards issuer classifies measures certain financial compared end private equity instruments characteristics liabilities equity statement investments compared end bristolmyers squibb com requires issuer classify financial instrument within scope liabil mon stock represented less assets us plans end ity initial adoption accounting pronouncement affect consolidated financial statements company provides comprehensive medical group life benefits may emerging issues task force reached consensus issue substantially us retirees elect participate companys compre revenue arrangements multiple deliverables issue addresses hensive medical group life plans asset allocation postretire certain aspects accounting vendor arrangements ment plans identical asset allocation described us perform multiple revenue generating activities companys revenue defined benefit pension plans recognition policies already conformed requirements consensus initial adoption affect consolidated financial statements accrual accounting significant assumptions april fasb issued sfas amendment statement consistent requirements sfas employers accounting derivative instruments hedging activities sfas amends sfas pensions company accounts pension benefits using accrual method requiring contracts comparable characteristics accounted recognizing pension expense payment benefits retirees similarly specifically statement clarifies circumstances contract accrual method accounting pension benefits necessarily requires actuarial initial net investment meets characteristics derivative clarifies assumptions concerning future events determine amount tim derivative contains financing component amends definition ing benefit payments underlying conform interpretation guarantors accounting companys key assumptions used calculating cost pension bene disclosure requirements guarantees including indirect guarantees fits discount rate rate compensation increase expected indebtedness othersfin discussed amends certain longterm rate return plan assets company consultation existing pronouncements initial adoption accounting pronounce actuaries evaluates key actuarial assumptions assumptions used ment material effect consolidated financial statements calculating cost pension benefits retirement turnover mortality bristolmyers squibb company annual reportiiiiirates based expectations actual experience appropriate determines reduction assumed discount rate reduction assumed discount assumptions december year calculate liability information rate increased present value future benefit obligations accordingly date pension expense following year depending effect increasing us plans pension expense contrast assumptions used pension expense could vary within range outcomes reduction assumed rate compensation increase decreased present value material effect reported earnings addition assumptions benefit obligations accordingly effect decreasing us plans materially affect accumulated benefit obligations future cash funding pension expense addition company revised based change actual results given year may differ estimated eco expectations future terminations retirements retirement turnover nomic factors assumptions revision decreased present value benefit obligations assumed discount rate used company determining future pension expense pension obligations us plans based indices aa aaarated following many years strong performance global equity market fell corporate bonds indices high quality corporate bonds selected reflect sharply sp declined cumulative weightedaverage remaining period benefit payments assumed rate reversed sp rose company reduced compensation increase used company determining future pension expected rate return us plan assets december obligations reflects estimate change actual future compensation maintained throughout levels due general price levels productivity seniority factors company expects net pension expense defined benefit net pension expense companys defined benefit pension pension plans included earnings minority interest income taxes plans included earnings minority interest income taxes approximately million higher million million compared million reflecting among things decrease assumed discount rate us plans pension expense determined using increase assumed rate compensation increase decrease assumed discount rate assumed rate compensation increase marketrelated value assets companys defined benefit pension present value benefit obligations december us plans plans rise global equity markets improved funded determined using assumed discount rate assumed discount rate status plans three difficult years since investment used determining us plans pension expense reduced gains losses recognized marketrelated value assets period expense would increased approximately million years however negative impact period felt assumed rate compensation increase used determining us plans following putting upward pressure pension expense pension expense reduced expense would company used assumed discount rates expected long decreased approximately million assumed discount rate used term rates return plan assets calculating cost pension benefits determining accumulated benefit obligation december cost postretirement benefits except case discount rate reduced accumulated benefit obligation would increased december rate used pension benefits versus million postretirement benefits reflect shorter duration us plans pension expense determined using expected postretirement liabilities longterm rate return plan assets expected longterm rate return us health care costs retiree population assumed increase plan assets used determining us plans pension expense trend expected increase per year reduced expense would increased million actual costs higher assumed likely put significant actual rates return earned us plan assets last ten years upward pressure companys expense retiree health care follows december president bush signed law medicare prescription drug improvement modernization act following guidance year return year return fasb staff position fas company elected defer recognition effect act accumulated postretirement benefit obligation net periodic postretirement benefit cost reflect effect act plan specific authoritative guidance accounting federal subsidy pending fasb guidance issued could require change previously reported information delayed recognition actuarial gains losses discussed gaap provides differences expected december unrecognized net actuarial losses actual returns recognized average future service employees companys defined benefit plans million million december company lowered assumed discount rate respectively based fair market value plan assets unrecognized us plans assumed rate compensation increase net actuarial losses reflect part decline fair market value plan assets raised following review recent experience reduction weightedaverage discount rate compensation assumed increase scale different rates different sfas provides delayed recognition actuarial gains losses ages rate disclosed december single rate including amounts arising changes estimated plan benefit obligations used age would produce present value benefit obligations due changes assumed discount rate differences actual methodology disclosure used calculating rate expected returns plan assets assumption changes sfas december rate december reduction requires unrecognized net actuarial gain loss determined based discount rate increase assumed rate compensation increase marketrelated value plan assets differs fair market value effect increasing present value benefit obligations accordingly calculated value recognizes changes fair value systematic rational effect increasing pension expense addition company manner five years amortized pension income expense revised based upon review experience assumption active mortality year extent unrecognized net actuarial loss gain exceeds revision effect increasing present value benefit obligations greater projected benefit obligation marketrelated value accordingly effect increasing pension expense plan assets beginning year net gains losses recognized december company lowered assumed discount rate pension income expense prospectively period approximates us plans reflect decline yields high quality average remaining service period active employees expected receive benefits corporate bonds assumed rate compensation decrease plans approximately years extent offset reflect expectations lower inflation future consistent losses gains subsequent years iiiii annual report bristolmyers squibb companyat december unrecognized net actuarial loss determined based substantially risks rewards ownership transferred case marketrelated value plan assets million amount sales made wholesalers result incentives ii excess exceeded greater projected benefit obligation market wholesalers ordinary course business inventory level iii time related value plan assets million december unrec understanding agreement course dealing consistent business practice ognized net actuarial loss determined based marketrelated value plan company would extend incentives based levels excess inventory assets million amount exceeded greater pro connection future purchases iv time incentives would jected benefit obligation market related value plan assets cover substantially vary directly wholesalers cost carrying million unless offset future unrecognized gains higher discount rates inventory excess wholesalers ordinary course business inventory level higher expected returns plan assets amortization million substantially risks rewards ownership transfer upon shipment unrecognized loss expected increase pension expense follow accordingly sales accounted using consignment ing ten years approximately million per year amount reflected model determination sales wholesaler meet fore higher expense expected going criteria involves evaluation variety factors number complex event fair market value pension plan assets particular plan judgments consignment model company recognize less accumulated benefit obligation plan yearend gaap revenue upon shipment product rather upon shipment product may require additional minimum liability circumstances company invoices wholesaler records deferred revenue gross invoice sales reduction stockholders equity establishment intangible asset price classifies inventory held wholesalers consignment inventory december fair market value companys defined benefit pension companys cost inventory company recognizes revenue plan assets million related accumulated benefit obligation net discounts rebates sales allowances accruals returns million company recognized additional minimum liability involve significant estimates judgments consignment inventory million cumulative million december longer subject incentive arrangements later set million charge comprehensive income included stock inventory sold wholesalers customers fifo basis holders equity december fair market value companys companys estimates inventory wholesalers deferred rev defined benefit pension plan assets million related accumu enue consigned inventory based projected prescription demand lated benefit obligation million company recognized addi based sales products well companys analysis thirdparty tional minimum liability million cumulative million information including information obtained certain wholesalers december offset creation million intangi respect inventory levels sellthrough customers thirdparty ble asset million charge comprehensive income included market research data companys internal information companys stockholders equity estimates subject inherent limitations estimates rely thirdparty data certain thirdparty information form estimates plan funding reflect limitations companys funding policy defined benefit plans contribute amounts provide current service fund past service liability acquired inprocess research development company contributed defined benefit plans million mil fair value inprocess research development acquired business lion respectively combination determined independent appraisal based present value research projects projected cash flows income approach utilized critical accounting policies consistent guidance practice aid issued american institute company prepares financial statements conformity account certified public accountants entitled assets acquired business combination ing principles generally accepted united states preparation finan used research development activities focus software electronic cial statements conformity gaap requires use estimates devices pharmaceutical industries future cash flows predominately based assumptions affect reported amounts assets liabilities including net income forecast project consistent historical pricing disclosure contingent assets contingent liabilities date finan margins expense levels similar products revenues estimated based cial statements reported amounts revenue expenses relevant market size growth factors expected industry trends individual reporting period companys critical accounting policies project life cycles life research projects underlying patent important companys financial condition results opera determining fair value research project expected revenues first tions require difficult subjective complex judgments adjusted technical risk completion resulting cash flows dis part management application often result need make counted rate approximating companys weighted average cost capital estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used impairment longlived assets preparation consolidated financial statements actual results may vary accordance sfas accounting impairment disposal estimates longlived assets company periodically evaluates whether current facts company believes following represent critical accounting circumstances indicate carrying value depreciable longlived policies summary companys significant accounting policies assets held used may recoverable circumstances including critical accounting policies discussed see note determined exist estimate undiscounted future cash flows produced accounting policies management companys independent accountants longlived asset appropriate grouping assets compared discussed companys critical accounting policies audit carrying value determine whether impairment exists asset deter committee board directors mined impaired loss measured based difference assets fair value carrying value estimate assets fair value revenue recognition based quoted market prices active markets available quoted market companys accounting policy revenue recognition substantial prices available estimate fair value based various valuation impact reported results relies certain estimates require techniques including discounted value estimated future cash flows difficult subjective complex judgments part management company reports asset disposed lower carrying value company recognizes revenue sales substantially risks estimated net realizable value rewards ownership transferred customer except case cer goodwill evaluated least annually impairment accordance tain transactions us pharmaceuticals wholesalers accounted sfas goodwill intangible assets sfas requires using consignment model gaap revenue recognized goodwill tested impairment using twostep process first step bristolmyers squibb company annual reportiiiiiidentify potential impairment second step measures amount determines earnings remitted foreseeable future additional impairment loss goodwill deemed impaired carrying tax provisions would required due complexities tax laws amount reporting units goodwill exceeds estimated fair value sfas assumptions would made practicable estimate requires indefinitelived intangible assets tested impairment amounts income taxes would provided using onestep process consists comparison fair value company evaluates need deferred tax asset valuation allowance carrying value intangible asset intangible assets deemed assessing whether likely realize deferred tax impaired net book value exceeds estimated fair value assets future assessment whether valuation allowance estimates future cash flows based reasonable supportable required often requires significant judgment including forecast future tax assumptions projections require managements judgment changes able income evaluation tax planning initiatives adjustments key assumptions companys businesses prospects deferred tax valuation allowance made earnings period changes market conditions could result impairment charge assessment made addition company operations tax jurisdictions located equity investments areas world subject audit jurisdictions tax audits company reviews equity investments impairment based nature often complex require several years resolve accruals determination whether decline market value investment tax contingencies require management make estimates judgments companys carrying value temporary making determi respect ultimate outcome tax audit actual results could vary nation company considers accounting principles board opinion estimates equity method accounting investments common stock sets outlook forth factors evaluated determining whether loss value recognized including companys ability hold investment market company expects growth opportunities exclusivity price market price fluctuations investments publicly traded shares challenges next several years estimates reductions net inability investee sustain earnings capacity would justify sales range billion levels products carrying amount investment companys investment imclone lost lose exclusivity protections specifically subject accounting see note alliances investments discus metformin franchise united states taxol europe monoprilin sion companys investment imclone united states canada pravastatin certain countries europe paraplatin united states serzonein united states sales rose result retirement benefits ing higher base generic competition develop companys pension plans postretirement benefit plans accounted expected thereby increasing expected level exclusivity losses using actuarial valuations required sfas employers accounting addition impact exclusivity losses paraplatinanticipated occur pri pensions sfas employers accounting postretirement benefits marily accelerated anticipated sixmonth exten pensions company considers accounting retirement plans sion exclusivity protection based pediatric studies obtained april critical management required make significant subjective judg amounts sales reductions exclusivity losses realization ments number actuarial assumptions including discount rates salary particular periods eventual levels remaining sales revenues growth longterm return plan assets retirement turnover health care cost uncertain dependent levels sales time exclusivity protection trend rates mortality rates depending assumptions estimates ends timing degree development generic competition speed used pension postretirement benefit expense could vary within range approvals market entry impact factors subject uncer outcomes material effect reported earnings addition tainties company estimates incremental exclusivity losses assumptions materially affect accumulated benefit obligations future measured net sales levels time exclusivity lost cash funding detailed discussion companys retirement benefits see billion billion years retirement benefits note pension postretirement company believes revenue loss less offset growth benefit plans revenues resulting growth companys inline products including plavix avaproavalide sustiva growth recently launched exclusive restructuring products abilify reyataz growth recently fda approved product downsize streamline operations rationalize manufacturing facilities erbitux introduction latestage pipeline products abat company periodically recorded restructuring charges result acept entecavir muraglitazar may approved within next thirty company made estimates judgments regarding future plans including six months begin contribute significantly additionally otn future termination benefits exit costs incurred restruc sales growth expected continue belief subject competitive factors turing actions take place actual results could vary estimates resulting including relating pravacholand adverse determination may adjustment earnings occur respect plavix patent litigation see businesscompetition note legal proceedings contingencies addition contingencies assurance company obtain required regulatory normal course business company subject contingencies approvals latestage pipeline products company expects result legal proceedings claims arising business cover wide ing product mix pressure company margins products losing range matters including government investigations shareholders suits prod exclusivity protection carry higher margins products expected grow sales uct liability environmental liability tax matters accordance sfas pravachol statin cholesterol companys largest product net accounting contingencies company records accruals con sales product beginning lose exclusivity markets tingencies probable liability incurred amount loss us exclusivity expected rate decline loss reasonably estimated discussion contingencies see note market share could accelerated recent clinical studies income taxes note legal proceedings contingencies company historically reviewed continue review cost base decisions may taken result reviews may result income taxes restructuring charges later year future periods december taxes provided approximately time company expects invest behind inline products research billion undistributed earnings foreign subsidiaries company development pipeline particularly latestage products reflected earn invested expects invest undistributed earnings indefinitely ings guidance external development licensing remain important ele future earnings repatriated united states company ments companys strategy potential cost impact iiiii annual report bristolmyers squibb companytransactions may entered future built tion companys products mature patents expire products iii companys plans guidance respect earnings technological advances patents attained competitors iv problems company subsidiaries subject number significant licensors suppliers distributors v business combinations pending lawsuits claims proceedings investigations possible among companys competitors major customers time reasonably assess final outcome investigations litigations difficulties delays inherent product development manufacturing management continues believe previously disclosed next sale products may appear promising development fail years aggregate impact beyond current reserves legal reach market number reasons including efficacy safety con matters affecting company reasonably likely material cerns inability obtain necessary regulatory approvals difficulty companys results operations cash flows may material excessive cost manufacture ii failure products achieve financial condition liquidity additional discussion matter see maintain commercial viability iii seizure recall products iv note legal proceedings contingencies failure obtain imposition limitations use loss patent companys expectations future sales growth described include intellectual property rights v failure company substantial expected increases sales plavix net sales approxi vendors suppliers comply current good manufacturing practices mately billion composition matter patent plavix application regulations quality assurance guidelines could expires currently subject litigation united states similar lead temporary manufacturing shutdowns product shortages delays proceedings involving plavix also instituted outside united states product manufacturing vi manufacturing distribution problems company continues believe patent valid legal difficulties including lawsuits claims proceedings investigations infringed alliance partner patentholder sanofi vigorously preclude delay commercialization products pursuing cases possible time reasonably assess adversely affect operations profitability liquidity financial condition come litigations adverse determination liti including intellectual property disputes ii adverse decisions litigation gations timing potential generic competition plavix however including product liability commercial cases iii inability obtain generic competition occur company believes unlikely adequate insurance respect type liability iv recalls pharma occur sometime loss market exclusivity plavix ceutical products forced closings manufacturing plants v government subsequent development generic competition would material investigations including relating wholesaler inventory financial companys sales plavix results operations cash flows could restatement product pricing promotion vi claims asserting viola material financial condition liquidity tions securities antitrust federal state pricing laws vii actual results may differ materially experience described environmental matters viii tax liabilities assurance factors could affect expectations described increase scope matters future cautionary factors may affect future results lawsuits claims proceedings investigations material increasing pricing pressures worldwide including rules practices managed cautionary factors may affect care groups institutional governmental purchasers judicial decisions future results governmental laws regulations related medicare medicaid annual report written oral statements company healthcare reform pharmaceutical reimbursement pricing general makes time time contain certain forwardlooking statements within fluctuations buying patterns inventory levels major distributors meaning section securities act section e retail chains trade buyers may result seasonality pric securities exchange act identify forwardlooking state ing wholesaler buying decisions including effect incentives offered ments fact use words expect anticipate estimate companys wholesaler inventory management policies including target may project guidance intend plan believe workdown changes wholesaler inventory levels factors words terms similar meaning expression connection greater expected costs difficulties including unanticipated discussion future operating financial performance one also iden effects difficulties acquisitions dispositions events includ tify forwardlooking statements fact relate strictly ing obtaining regulatory approvals connection evolving business torical current facts forwardlooking statements based current strategies legal defense costs insurance expense settlement costs risk expectations involve inherent risks uncertainties including factors adverse decision related litigation could delay divert change could cause actual outcomes changes advertising promotional spending categories differ materially current expectations statements likely relate spending may affect sales among things companys goals plans projections regarding changes product mix may affect margins financial position results operations market position product development changes companys structure operations revenues costs staffing product approvals sales efforts expenses performance results current efficiency resulting acquisitions divestitures mergers alliances restruc anticipated products outcome contingencies legal proceed turings strategic initiatives ings financial results based current expectations involve economic factors company control changes inherent risks uncertainties including internal external factors could business economic conditions including limited changes delay divert change next several years interest rates fluctuation foreign currency exchange rates although possible predict identify factors may include changes business political economic conditions due political limited following social instability military armed conflict nationalization assets debt new government laws regulations health care reform initia payment moratoriums restrictions commerce actual threat tives united states state federal level countries ened terrorist attacks united states parts world ii changes fda foreign regulatory approval processes may related military action cause delays approving preventing approval new products iii changes accounting standards promulgated fasb sec tax changes phasing tax benefits heretofore available aicpa may require adjustments financial statements united states certain foreign countries iv new laws regulations capacity efficiency reliability security potential breakdown invasion judicial decisions affecting pricing marketing within across jurisdictions destruction interruption information systems v changes intellectual property law reliance company vendors partners third parties meet competitive factors new products developed competitors contractual regulatory obligations relation arrange lower prices superior performance features otherwise com ments company petitive bristolmyers squibbs current products ii generic competi results clinical studies relating companys competitors products bristolmyers squibb company annual reportiiiiialthough company believes prudent plans assump company uses derivative instruments part interest rate risk man tions assurance given goal plan set forth forwardlook agement policy derivative instruments used include interest rate swaps ing statements achieved readers cautioned place undue subject fairvalue hedge accounting treatment reliance statements speak date made company executed several fixed floating interest rate swaps con company undertakes obligation release publicly revisions forward vert billion companys fixed rate debt paid looking statements result new information future events otherwise variable rate debt year ended december company recognized net reduction interest expense million quantitative qualitative reflects benefit lower floating rate obtained swap agree disclosures market risk ment sfas requires revaluation fair value swap contracts company exposed market risk due changes currency exchange well underlying debt hedged swap contracts rates interest rates reduce risk company enters certain underlying debt revalued resulting increase current assets derivative financial instruments available costeffective basis longterm debt million swap contracts generally held matu hedge underlying economic exposure instruments managed rity used speculative purposes following table summarizes consolidated basis efficiently net exposures thus take advantage interest rate swaps outstanding december natural offsets derivative financial instruments used speculative pur poses gains losses hedging transactions offset gains losses notional amount variable underlying exposures hedged ineffective portion hedges underlying rate reported earnings occurs dollars millions debt received maturity fair value foreign exchange option contracts forward contracts used hedge interest rate contracts anticipated transactions companys primary foreign currency exposures swaps associated month us relation us dollar euro japanese yen canadian dollar notes due libor mexican peso table summarizes companys outstanding foreign exchange swaps associated month us contracts december fair value foreign exchange con notes due libor tracts based yearend currency rates blackscholes model swaps associated month us case option contracts fair value option contracts forward con notes due libor tracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations swaps associated month us eign currency exchange rates notes due libor weighted dollars millions average notional fair except currency rates strike price amount value maturity following table summarizes interest rate swaps outstanding foreign exchange forwards december australian dollar brazilian real notional british pound amount variable underlying rate canadian dollar dollars millions debt received maturity fair value euro interest rate contracts japanese yen south african rand swaps associated month us swedish krona notes due libor swiss franc swaps associated month us total contracts notes due libor december company held option contracts aggre gate notional amount fair value million million respec estimated change interest rate structure would tively contracts granted right sell euros canadian australian material impact companys consolidated financial position results dollars company also held forward contracts aggregate notional operations cash flows amount million fair value liability million company also outstanding several interest rate foreign currency contracts primarily related exposures euro swaps related japanese yen notes due aggregate fair value instruments december million million respectively company million million longterm debt outstanding december respectively see note short term borrowings longterm debt note financial instruments additional information company maintains cash cash equivalents marketable securities various financial institutions order limit exposure one finan cial institution financial institutions headquartered primarily north america europe iiiii annual report bristolmyers squibb companyconsolidated statement earnings year ended december restated restated dollars millions except per share data earnings net sales cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring items litigation charges net gain sales businessesproduct lines asset impairment charge investment imclone equity net income affiliates expense net total expenses earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations discontinued operations net earnings net gain disposal net earnings earnings per common share basic earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted earnings continuing operations discontinued operations net earnings net gain disposal net earnings average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements bristolmyers squibb company annual reportiiiiiconsolidated statement comprehensive income retained earnings restated restated dollars millions comprehensive income net earnings comprehensive income foreign currency translation net tax benefit deferred losses derivatives qualifying hedges net tax benefit minimum pension liability adjustment net tax benefit available sale securities net taxes total comprehensive income comprehensive income retained earnings retained earnings january net earnings cash dividends declared zimmer common stock dividend retained earnings december accompanying notes integral part financial statements iiiii annual report bristolmyers squibb companyconsolidated balance sheet december restated dollars millions assets current assets cash cash equivalents marketable securities receivables net allowances inventories including consignment inventory deferred income taxes net valuation allowances prepaid expenses total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses accrued rebates returns us foreign income taxes payable dividends payable accrued litigation liabilities deferred revenue consigned inventory total current liabilities liabilities longterm debt total liabilities commitments contingencies stockholders equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares issued capital excess par value stock restricted stock accumulated comprehensive loss retained earnings less cost treasury stock common shares total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements bristolmyers squibb company annual reportiiiiiconsolidated statement cash flows year ended december restated restated dollars millions cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization provisions deferred income taxes acquired inprocess research development litigation charges asset impairment charge investment imclone provision restructuring items gain sales businessesproduct lines including discontinued operations loss gain disposal property plant equipment equity net income affiliates impairment charges asset writeoffs litigation settlement payments minority interest net distributions taxes pension contributions changes operating assets liabilities receivables inventories prepaid expenses assets deferred revenue consigned inventory accounts payable accrued expenses us foreign income taxes payable liabilities net cash provided operating activities cash flows investing activities proceeds sales maturities marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds disposal property plant equipment proceeds sales businessesproduct lines proceeds sale clairol purchase dupont pharmaceuticals clairol dupont pharmaceuticals divestiture acquisition costs investment companies purchases trademarks patents licenses net cash used investing activities cash flows financing activities shortterm borrowings net repayments longterm debt borrowings longterm debt repayments issuances common stock stock plans purchases treasury stock dividends paid net cash used provided financing activities effect exchange rates cash increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part financial statements iiiii annual report bristolmyers squibb companynotes consolidated statements note based sales products well companys analysis thirdparty accounting policies information including information obtained certain wholesalers throughout notes consolidated financial statements certain prior respect inventory levels sellthrough customers thirdparty periods prior period comparisons reflect balances amounts market research data companys internal information companys restated basis information restatement see note restatement estimates subject inherent limitations estimates rely thirdparty previously issued financial statements years ended december data certain thirdparty information form estimates reflect limitations basis consolidation sales rebate return accruals consolidated financial statements include accounts bristolmyers medicaid rebate accruals million million december squibb company bms company bristolmyers squibb respectively managed healthcare rebate accruals controlled majority owned subsidiaries intercompany balances transac million million december respectively tions eliminated certain prior year amounts reclassified rebate accruals established period related conform current year presentation including reclassification revenue recognized resulting reduction sales establishment amounts relating equity net income affiliates formerly net liability included accrued liabilities accrual recorded based ted minority interest net taxes presented separate line estimate proportion recorded revenue result rebate consolidated statement earnings see also investments return prime vendor chargeback accruals established similar manner recorded reduction accounts receivable million use estimates million december respectively preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates income taxes assumptions affect reported amounts assets liabilities disclo provision income taxes determined using asset lia sure contingent assets contingent liabilities date financial bility approach accounting income taxes approach deferred statements reported amounts revenues expenses taxes represent future tax consequences expected occur reported reporting period significant assumptions employed estimates amounts assets liabilities recovered paid provision income used determining values intangible assets restructuring charges accru taxes represents income taxes paid payable current year plus als sales rebate return accruals legal contingencies tax assets tax lia change deferred taxes year deferred taxes result differences bilities well estimates used applying revenue recognition policy financial tax bases companys assets liabilities accounting retirement postretirement benefits including actu adjusted changes tax rates tax laws changes enacted arial assumptions actual results could differ estimated results valuation allowances recorded reduce deferred tax assets likely tax benefit realized company revenue recognition record provision income taxes undistributed earnings foreign company recognizes revenue substantially risks rewards subsidiaries expect repatriate foreseeable future ownership transferred customer case certain sales made company establishes liabilities possible assessments taxing author nutritionals healthcare segments certain nonus busi ities resulting known tax exposures amounts represent reasonable nesses within pharmaceuticals segment revenue recognized date provision taxes ultimately expected paid may need adjusted receipt purchaser revenues reduced time sale reflect time information becomes known expected returns estimated based historical experience additionally provisions made time sale discounts rebates estimated cash cash equivalents sales allowances based historical experience updated changes facts cash equivalents primarily highly liquid investments original matu circumstances appropriate provisions recorded reduction rities three months less time purchase recorded cost revenue approximates fair value case sales made wholesalers result incentives ii excess wholesalers ordinary course business inventory level iii marketable securities time understanding agreement course dealing consis company accounts marketable securities accordance tent business practice company would extend incentives based levels statement financial accounting standard sfas accounting excess inventory connection future purchases iv time certain investments debt equity securities company determined incentives would cover substantially vary directly whole appropriate classification marketable securities availableforsale salers cost carrying inventory excess wholesalers ordinary course time purchase december business inventory level substantially risks rewards ownership companys investments marketable securities reported fair value transfer upon shipment accordingly sales accounted unrealized gains losses reported component accumulated using consignment model determination sales comprehensive income loss stockholders equity amortized cost debt wholesaler meet foregoing criteria involves evaluation variety factors securities adjusted amortization premiums accretion discounts number complex judgments consignment model date purchase maturity amortization included interest company recognize revenue upon shipment product rather upon income addition deduction coupon interest earned shipment product company invoices wholesaler records deferred rev investments company follows investment managers method deter enue gross invoice sales price classifies inventory held whole mining cost basis computing realized gains losses sale saler consignment inventory companys cost inventory availableforsale securities average cost method realized gains company recognizes revenue consignment inventory longer sub losses included income expense ject incentive arrangements later inventory sold marketable securities classified available sale recorded wholesalers customers firstinfirstout fifo basis cost approximates fair value companys estimates inventory wholesalers deferred rev enue consigned inventory based projected prescription demand bristolmyers squibb company annual reportiiiiinotes consolidated statements inventory valuation adjusts investments fair value decline market value inventories generally stated average cost excess market deemed temporary company recorded asset impairment charge million otherthantemporary decline capital assets depreciation market value imclone systems incorporated imclone expenditures additions renewals improvements capitalized longterm investments securities comprise marketable equity secu cost depreciation generally computed straightline method based rities securities investments market values readily estimated useful lives related assets estimated useful lives available included assets marketable equity securities classified major classes depreciable assets years buildings years availableforsale reported fair value fair value based quoted mar machinery equipment fixtures company periodically evaluates ket prices end reporting period securities investments whether current events circumstances indicate carrying value market values readily available carried cost unrealized gains depreciable assets may recoverable losses reported net related tax effects component accu mulated comprehensive income loss stockholders equity sold impairment longlived assets time sale gains losses calculated specific identification effective january company adopted provisions sfas method recognized incomeexpense losses also recognized accounting impairment longlived assets adoption sfas income decline market value deemed otherthantemporary material effect consolidated financial statements company sfas establishes accounting impairment goodwill intangible assets longlived tangible intangible assets goodwill disposal company adopted sfas goodwill intangible assets segment business pursuant sfas company periodi january certain provisions adopted july cally evaluates whether current facts circumstances indicate carrying respect amortization goodwill arising acquisitions made june value depreciable assets held used may recoverable sfas addresses initial recognition measurement circumstances determined exist estimate undiscounted future cash intangible assets acquired outside business combination recognition flows produced longlived asset appropriate grouping assets measurement goodwill intangible assets subsequent compared carrying value determine whether impairment exists acquisition new rules goodwill longer amortized subject asset determined impaired loss measured based differ annual impairment tests connection accounting change ence assets fair value carrying value estimate goodwill resulting companys acquisition dupont pharmaceuticals assets fair value based quoted market prices active markets available business dupont pharmaceuticals investment imclone amortized quoted market prices available estimate fair value based goodwill arising business acquisitions prior july various valuation techniques including discounted value estimated future amortized straightline basis periods ranging years cash flows company reports asset disposed lower goodwill amortized effective january goodwill amorti carrying value estimated net realizable value zation expense million accordance sfas goodwill tested impairment upon capitalized software adoption new standard annually thereafter sfas requires certain costs obtain internal use software significant systems projects goodwill tested impairment using twostep process first step capitalized amortized estimated useful life software identify potential impairment second step measures amount ranges four years costs obtain software projects impairment loss goodwill deemed impaired carrying significant expensed incurred capitalized software net accumulated amount reporting units goodwill exceeds estimated fair value amortization included assets million million company completed goodwill impairment assessment indicated december respectively impairment goodwill intangible assets consisting patents trademarks technology investments licenses amortized straightline basis useful lives ranging january company adopted financial accounting standards years sfas requires indefinitelived intangible assets board fasb interpretation fin interpretation consolidation tested impairment using onestep process consists compari variable interest entities interpretation arb fin clarifies son fair value carrying value intangible asset intangible application accounting research bulletin consolidated financial assets deemed impaired net book value exceeds estimated statements certain entities equity investors charac fair value intangible assets evaluated impairment accordance teristics controlling financial interest sufficient equity risk sfas described impairment longlived assets entity finance activities without additional subordinated financial support parties entities known variable interest entities product liability vies fasb issued revision fin fin r december accruals product liability recorded undiscounted basis fin r effective interim period ending march new probable liability incurred amount liability existing vies adoption fin effect companys reasonably estimated based existing information accruals financial statements adjusted periodically assessment efforts progress additional information entity meet definition vie fin becomes available receivables related insurance thirdparty recover company accounts entity provisions accounting principles ies product liabilities recorded undiscounted basis board apb opinion equity method accounting investments probable recovery realized classified reduction litigation common stock requires company consolidates majority charges consolidated statement earnings owned subsidiaries ability exercise control company accounts less owned companies contingencies ability exercise significant influence using equity method accounting normal course business company subject contingencies companys share net income losses equity investments included legal proceedings claims arising business cover wide equity net income affiliates consolidated statement earnings range matters including among others product liability environmental lia company periodically reviews equity investments impairment bility tax matters accordance sfas accounting iiiii annual report bristolmyers squibb companynotes consolidated statements contingencies company records accruals contingencies try trends individual project life cycles life research projects probable liability incurred amount loss reason underlying patent determining fair value research project ably estimated discussion contingencies reference made note expected revenues first adjusted technical risk completion result income taxes note legal proceedings contingencies ing cash flows discounted rate approximating companys weighted average cost capital acquired inprocess research devel derivative financial instruments opment expensed incurred underlying product received derivative financial instruments used company principally regulatory approval future alternative use addition management interest rate foreign currency exposures company costs nonrefundable related acquisition licensing products hold issue derivative financial instruments speculative purposes yet received regulatory approval marketed company records derivative instruments balance sheet fair alternative future use charged earnings incurred value changes derivatives fair value recognized earnings unless spe cific hedge criteria met derivative designated fair value hedge earnings per share changes fair value derivative hedged item attributable basic earnings per common share computed using weightedaverage hedged risk recognized charge credit earnings deriva number shares outstanding year diluted earnings per common tive designated cash flow hedge effective portions changes share computed using weightedaverage number shares outstanding fair value derivative recorded comprehensive income loss year plus incremental shares outstanding assuming exercise subsequently recognized consolidated statement earnings dilutive stock options convertible instruments hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire stock compensation plans change fair value included measurement hedge effectiveness company applies apb opinion accounting stock issued cash flow hedges ineffective portions changes fair value cash flow employees related interpretations accounting stockbased compen hedges recognized charge credit earnings sation plans company recognize compensation expense stock company designates assigns derivatives hedges forecasted options granted plans exercise price option date transactions specific assets specific liabilities hedged assets liabili grant equal fair market value date grants restricted ties sold extinguished forecasted transactions hedged stock company recognizes compensation expense straightline basis longer expected occur company immediately recognizes gain loss period restrictions expire designated hedging financial instruments consolidated statement following table summarizes companys results pro forma basis earnings recorded compensation expense based upon fair value grant date awards plans consistent methodology prescribed shipping handling costs sfas accounting stockbased compensation company typically charge customers shipping handling costs shipping handling costs included marketing selling administrative expenses million restated restated million million respectively dollars millions except per share data advertising costs net earnings advertising costs expensed incurred advertising expense mil reported lion million million respectively deduct total stockbased employee compensation expense determined milestone payments fair value based method awards company time time enter strategic alliances net related tax effects third parties give company rights develop manufacture market pro forma andor sell pharmaceutical products rights owned third parties result alliances company may obligated make basic earnings per share payments alliance partners contingent upon achievement certain pre reported determined criteria milestones achieved prior marketing approval pro forma product payments expensed research development prod uct approval additional milestones capitalized amortized cost diluted earnings per share products sold remaining useful life asset capitalized milestone reported payments tested recoverability whenever events changes circum pro forma stances indicate carrying amounts may recoverable see note stockholders equity additional information acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research projects projected cash flows income approach uti lized consistent guidance practice aid issued american institute certified public accountants aicpa entitled assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected indus bristolmyers squibb company annual reportiiiiinotes consolidated statements note sales products divested division made prior divestiture required restatement previously issued gaap financial statements years ended december adjustments earnings continuing operations company restated consolidated balance sheet december minority interest income taxes consolidated statements earnings cash flows comprehensive international pension employee benefit plan accrual historically income retained earnings years ended december company erroneously accounted certain international employee bene restatement affected periods prior impact restatement fit plans cash nongaap methods based belief prior periods reflected adjustment retained earnings impact applying accrual method required gaap immaterial january addition restatement impacts first second third company actuarial analysis performed larger quarters restated amounts quarters comparable plans determined understated benefits liabilities interim periods presented note selected quarterly financial plans company accounts pension employee benefit data unaudited restatement corrects certain company 's plans accrual method addition company failed make historical accounting policies conform gaap ii corrects certain required accrual one international employee benefit plans due mis errors made application gaap set forth restatement application gaap adjustments included restatement previously issued financial state intercompany accounts company determined certain unreconciled ments years ended december intercompany accounts payable receivable aggregating net balance error within meaning apb opinion accounting changes million written prior january following table presents impact restatement adjustments marketing selling administrative adjustments company described net earnings years ended december recorded number adjustments respect marketing selling admin retained earnings january istrative expense company determined error application historical accounting policy accruing earned vacation retained yet taken company determined properly recorded earnings net earnings expense training operational support relating contract third year ended december january party period incurred company wrote certain dollars millions accounts adequate documentation supporting existence reported company also wrote reserves postemployment benefits wic rebates accrual pensions retained error certain divested businesses goods transit company incorrectly capitalized certain costs related internally devel net sales adjustments oped software due misapplication gaap company also failed international pension adjust certain expense reserves timely basis actual amount expense employee benefit plan accrual incurred required gaap company also corrected number intercompany accounts smaller immaterial errors application gaap marketing selling intercompany foreign exchange gains losses historically company administrative adjustments deferred gains losses certain intercompany foreign exchange loan trans intercompany foreign actions recording gains losses accumulated comprehensive exchange gains losses loss company 's consolidated balance sheet error restatement items application gaap requires unless intercompany transaction adjustments minority longterm investment settlement planned fore interest net taxes seeable future foreign currency transaction gain loss included provision income taxes determining net income company corrected policy comply restated gaap restatement items company several foreign subsidiaries adjustments net sales related adjustments cost products sold operate jurisdictions hyperinflationary currencies respect wic rebates accrual historically company accrued rebates company recorded restatement adjustments correct errors relating women infants children wic program date coupons accounting deferred tax assets liabilities valuation allowances issued states error application gaap result company record foreign exchange gain loss respect requires accrual date sale product company corrected deferred tax assets error company erroneously policy accrue wic rebates date sale accrued expenses relating certain grants completed fail goods transit company corrected error application gaap ing adjust accruals actual amounts expenses incurred life regarding timing revenue recognition certain sales made mead grants company failed write unreconciled account relating johnson nutritionals mead johnson unit healthcare unit cer acquisition dupont pharmaceuticals company also failed tain nonus pharmaceuticals units company previously recorded adjust certain expense reserves timely basis actual amount revenue products sold date shipment records revenue expense incurred required gaap company also corrected number based terms sale date receipt purchaser smaller immaterial errors application gaap net sales adjustments company corrected error accounting managed health care sales rebate accrual amounts initially recorded adjustments minority interest net taxes connection companys previous restatement company restated company recorded duplicate deferred tax net assets error related certain sales transactions made certain asia business units rev tax attributes certain partnership entities sanofisynthlabo sanofi enue recognized error prior transfer substantially owns majority controlling interest risks rewards ownership due existence right return available purchaser product company erroneously failed adjust timely basis accrual sales returns charge backs deductions iiiii annual report bristolmyers squibb companynotes consolidated statements adjustments provision income taxes adjustments cash cash equivalents classification contingency reserves certain instances periods restated company determined certain investments cash man company made errors recording reserves tax contingencies agement program erroneously classified cash equivalents consoli company believes may inappropriate adjustments tax dated balance sheet december statement cash contingency reserves company completed review flows fiscal years respectively approximately billion able determine whether errors tax billion investments held company reflected contingency reserves corrected restatement related inappro cash cash equivalents companys consolidated balance sheet priate accounting december respectively although company believes us federal state tax items company identified number errors investments highly liquid maturities investments related current deferred federal state taxes corresponding cur exceeded three months previous presentation cash cash equivalents rent deferred tax expense errors included establishing deferred error company restated prior periods present invest tax assets extent necessary corresponding valuation allowances ments marketable securities restatement adjustment companys net operating loss tax credit carryforwards ii applying misapply consolidated balance sheet december decreased amount cash ing asset liability approach deferred taxes required gaap iii cash equivalents approximately billion restatement adjustment considering relevant information date issuance financial statements cash flows increased amount net cash used investing statements iv timely adjusting differences tax provisions activities years ended december approximately filed tax returns billion billion respectively foreign tax items company identified number errors related cur rent deferred foreign taxes corresponding tax expense errors adjustments expense net classification included establishing deferred tax assets extent necessary cor table presents restatement charges credits certain responding valuation allowances net operating loss tax credit carryfor amounts classified error reclassified part wards ii applying misapplying asset liability approach restatement expense net appropriate line item consoli deferred taxes required gaap iii considering information avail dated statement earnings years ended december able date issuance financial statements iv timely adjusting filed tax returns v accounting income taxes certain jurisdictions year ended december cash basis dollars millions following table presents impact restatement adjustments total adjustments described provision income taxes expense net earnings net sales rebate accrual adjustment minority interest income taxes cost products sold dollars millions royalty expense provision income taxes product liability expense previously reported royalties receivable writeoff adjustment neta contingency reserves tax items us marketing selling administrative nonus amortization capitalized software provision income taxes restricted stock grant amortization restated neta following table presents impact income tax restatement adjust ments described companys consolidated balance sheet advertising product promotion december neta contingency tax research development dollars millions reserves items reimbursement assets clinical study expenditures deferred income taxes current neta deferred income taxes noncurrent liabilities equity net income affiliates accrued liabilities imclone share losses us foreign income taxes payable certain items included net reclassifications amounts errors within meaning apb opinion accounting changes rather amounts reclassified conform current year presentation bristolmyers squibb company annual reportiiiiinotes consolidated statements note following table presents impact restatement adjustments alliances investments companys previously reported results condensed basis sanofisynthlabo company agreements sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor previously previously antagonist indicated treatment hypertension plavix clopidogrel dollars millionsexcept per share data reported restated reported restated platelet inhibitor worldwide alliance operates framework statement earnings two geographic territories one americas australia europe asia two territory partnerships formed manage central net sales expenses marketing research development royalties total costs expenses supply finished product individual countries country level agree ments either copromote whereby partnership formed par earnings ties sell brand comarket whereby parties operate sell continuing operations brands independently place discontinued operations company acts operating partner territory covering net lossearnings americas principally united states canada puerto rico latin net gain disposal american countries australia owns majority controlling interest net earnings territory company consolidates country partnership results territory records sanofis share results minority interest basic earnings per common share net taxes million million continuing operations million company recorded sales territory comarket discontinued operations ing countries germany italy spain greece million net earnings million million net gain disposal sanofi acts operating partner territory covering europe asia net earnings owns majority financial controlling interest territory company accounts investment partnership entities terri diluted earnings per common share tory equity method records share results equity net continuing operations income affiliates consolidated statement earnings companys discontinued operations share net income partnership entities taxes mil net earnings lion million million net gain disposal company sanofi formed alliance copromotion net earnings irbesartan part company contributed irbesartan distribu tion rights united states sanofi paid company total balance sheet december million company accounts transaction sale interest license defers amortizes million income assets expected useful life license approximately years current assets company amortized income million cash cash equivalents million marketable securities current assets otsuka total current assets company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify arip assets iprazole treatment schizophrenia total milestone payments made total assets otsuka december million million expensed acquired inprocess research development liabilities million capitalized payments amortized remaining current liabilities life agreement approximately years company began liabilities copromoting product otsuka united states puerto rico longterm debt november company also copromote product several total liabilities european countries marketing approval received european author ities revenue earned otsuka ships product title passes stockholders equity customer company records alliance revenue share net sales copromotion countries records expenses related total liabilities product company also exclusive right sell abilify number stockholders equity countries europe latin america asia countries sales com mence company record net sales related cost sales company recorded revenue abilify million million imclone november company purchased million shares imclone per share million represented approximately imclone shares outstanding prior companys commencement iiiii annual report bristolmyers squibb companynotes consolidated statements public tender offer imclone shares transaction accounted million paid equity investment mil using equity method accounting imclone biopharmaceutical com lion milestone payment million million expensed pany focused developing targeted cancer treatments include growth acquired inprocess research development remaining factor blockers cancer vaccines antiangiogenesis therapeutics equity million recorded equity investment additional million investment imclone part strategic agreement company added investment primarily acquisition costs resulting carrying imclone also includes arrangement codevelop copromote value million december third quarter cancer drug erbitux series payments originally totaling billion company recorded pretax charge earnings million company paid imclone milestone payment million temporary decline market value imclone based decline december imclone announced us food drug value imclones shares fair value equity investment administration fda refused accept filing biologics license imclone used record impairment determined based market applicationbla submitted imclone erbitux value imclone shares september total equity investment bla submitted gain marketing approval treat irinotecanrefrac imclone december million compared million tory colorectal carcinoma december per share basis carrying value march agreement imclone revised reduce imclone investment closing market price imclone shares total payments million billion revised agreement december respectively compared company paid imclone million march million respectively december closing market price march million march approval erbitux imclone shares march per share fda additional million upon achievement second company recorded million net loss share imclones losses milestone million paid imclone march included million loss million related million expensed inprocess research development first imclones restatement results final reporting full year quarter remaining million recorded additional first quarter results company recorded million net loss equity investment eliminate income statement effect portion share imclones losses amortization previously capitalized mile milestone payment company economic claim stone payments company records share results equity net ownership interest imclone also revised agreement company income affiliates consolidated statement earnings pay imclone distribution fee based flat rate product net february fda approved resubmitted bla revenues north america company purchase commercial erbitux erbitux treatment patients epidermal growth requirements bulk erbitux imclone price equal actual man factor receptor egfr expressing metastatic colorectal cancer failed ufacturing cost plus terms revised agreement continue irinotecanbased regimen combination irinotecan monother apy patients intolerant irinotecan fourth quarter company recorded pretax charge approximately million comprised million writeoff summary financial information acquired inprocess research development related equity investment following summarized financial information companys equity million writeoff portion million milestone investments imclone joint venture sanofi europe asia payment made remaining million million mile stone payment recorded additional equity investment eliminate income statement effect portion milestone payment dollars millions company economic claim ownership interest imclone acquired inprocess research development charge related three oncol revenues ogy research projects phase later stage development one gross profit research project erbitux amount determined identifying net income research projects areas technological feasibility estab current assets lished alternative future use projected fda noncurrent assets approval dates used years time company current liabilities expected projects begin generate cash flows cost complete noncurrent liabilities projects estimated million research develop information includes imclone data date investment ment projects considered valuation subject normal risks november uncertainties associated demonstrating safety efficacy required obtain fda approval purchase price allocation resulted million patent technology intangible assets amortized weightedaverage useful lives years approximately million goodwill amortized bristolmyers squibb company annual reportiiiiinotes consolidated statements note following table presents detail provision restructuring restructuring items items operating segment type company allocate restruc activities turing charges business segments company recorded pretax restructuring charges employee million relating downsizing streamlining worldwide operations employee termination exit rationalization worldwide manufacturing operations charge dollars millions terminations benefits costs items total million primarily relates employee termination benefits approximately employees including manufacturing administrative sales personnel pharmaceuticals europe north america asia central america items million nutritionals relate primarily relocation expenses result consolidation research healthcare facilities charges partially offset adjustment due changes corporateother estimates prior period reserves million principally due subtotal higher anticipated proceeds disposal assets reduced separation reduction reserves changes estimates costs company expects complete restructuring activities provisions restructuring items addition company recorded million asset impairments accelerated depreciation relating rationalization manufacturing opera activities tions cost products sold company recorded pretax restructuring charges following table presents detail provision restructuring million restructuring programs included termination benefits items operating segment type company allocate restruc asset writedowns costs implemented downsize turing charges business segments streamline operations rationalize manufacturing facilities terminate employee certain sales force research contract obligations actions substan employee termination exit tially completed charge million relates employee termination dollars millions terminations benefits costs items total benefits employees result companywide restructuring effort pharmaceuticals downsize streamline operations impacted virtually areas healthcare including sales force manufacturing administrative research personnel subtotal additional charges include million termination contract sales reduction reserves changes estimates force million exit costs primarily related costs associated provision restructuring items closure certain manufacturing operations charge also included million writedown fixed assets primarily related exit company also recorded million research development nutritionals business eastern europe closure pharmaceutical related upfront payments four licensing agreements production facility united states closure research facility allocated business segments france items million relate costs associated product recall restructuring charges partially offset reversal mil activities lion result change estimate relating separation costs cancellation company recorded pretax restructuring charges projects previously provided million relating reduction elimination nonstrategic research additional costs associated restructuring projects include efforts well consolidation research facilities workforce reductions million sales deductions customer charge backs relating abandonment downsizing streamlining worldwide operations charge nonstrategic pharmaceutical product lines included million relates employee termination benefits approximately reduction sales million related inventory writeoffs employees including research manufacturing sales administrative person included cost products sold nel million represents asset writedowns including million impair following table presents detail provision restructuring ment charge companys investment deltagen million items operating segment type company allocate restruc exit costs closure facilities related expenses turing charges business segments charges offset adjustment prior period restructuring reserves million million due lower expected separation employee asset employee termination write exit costs million due higher anticipated proceeds disposal dollars millions terminations benefits downs costs items total assets previously written restructuring million projects cancelled addition million adjustment cost products pharmaceuticals sold made reflect reversal inventory reserves associated nutritionals celled projects company substantially completed restructuring activi healthcare ties corporateother addition million accelerated depreciation relating planned subtotal shutdown research facilities united states included research reduction reserves changes estimates development expense million inventory writeoffs associated provisions restructuring items projects included cost products sold iiiii annual report bristolmyers squibb companynotes consolidated statements rollforward technological feasibility established restructuring charges spending liabilities associated prior alternative future use two projects terminated three remaining current actions follows projects two clinical stage one preclinical currently proceeding employee research development projects considered valuation subject termination exit cost normal risks uncertainties associated demonstrating safety dollars millions liability liability total efficacy required fda approval balance december connection acquisition company recorded million charges restructuring liabilities result severance relocation workforce spending elimination duplicate facilities contract terminations costs changes estimate recognized company liability assumed acquisition balance december date resulting additional goodwill liabilities consisted million charges employee termination benefits approximately employees mil spending lion related closure facilities million contract termina changes estimate tions million originally recorded accrued expenses reduced balance december million december million december charges million end reduction balance spending due cash payments million adjustment reverse previously changes estimate recorded liabilities million corresponding reduction goodwill balance december adjustment primarily due lower expected separation costs con tract termination expenses facilities exit costs related acquisi liabilities included accrued expenses consolidated balance tion reduction balance due cash payments sheet million following unaudited pro forma financial information presents results note acquisition occurred beginning acquisitions divestitures dupont pharmaceuticals acquisition restated october company acquired dupont pharmaceuticals dollars millions except per share data year ended december e du pont de nemours company billion cash results dupont pharmaceuticals included consolidated financial state net sales ments date acquisition dupont pharmaceuticals primarily net earnings domestic pharmaceutical imaging product business focused research earnings per sharebasic development acquisition financed proceeds issuance earnings per sharediluted billion commercial paper issuance billion mediumterm notes internal cash flows unaudited pro forma results prepared comparative pur following summary final allocation purchase price poses include certain adjustments additional amortization estimated fair values assets acquired liabilities assumed dollars mil expense result identifiable intangible assets arising acquisition lions increased interest expense acquisition debt exclude acquired inprocess research development charge related dupont current assets pharmaceuticals acquisition pro forma net earnings earnings per share property plant equipment amounts include billion gain sale clairol pro forma results intangible assets necessarily indicative either results operations actually acquired inprocess research development would resulted acquisition effect beginning goodwill respective periods future results assets total assets acquired current liabilities company completed sale two branded products restructuring liabilities moisturel duricef resulted pretax gain million acquisition liabilities company completed sale three pharmaceutical products longterm liabilities corzide delestrogen florinef licensing rights corgard united totalliabilities assumed states estrace tablets apothecon commodity business solage purchase price viactiv product lines resulted pretax gain million total intangible assets million amortized weightedaverage useful lives include core developed technology million years weightedaverage useful life respectively patents million year weightedaverage useful life goodwill million assigned pharmaceuticals seg ment total amount million expected deductible tax purposes year period time acquisition billion purchase price allocated acquired inprocess research development charged earnings fourth quarter charge associated five research proj ects amount determined identifying research projects bristolmyers squibb company annual reportiiiiinotes consolidated statements note note discontinued operations earnings per share company completed sale clairol procter gamble numerator basic diluted earnings per share net earnings cash proceeds approximately billion sale resulted pretax gain available common stockholders denominator basic earnings per billion billion taxes included gain dis share weightedaverage number common shares outstanding posal discontinued operations addition company spun period denominator diluted earnings per share weightedaverage zimmer holdings inc zimmer taxfree distribution resulting com shares outstanding adjusted effect dilutive stock options compu mon stock dividend million company resolved several tations basic earnings per common share diluted earnings per common postclosing matters associated previously discontinued businesses result share follows ing increase million gain disposal clairol year ended december million credit related reduction tax contingency reserve related restated restated spinoff zimmer million credit retained earnings related dollars millions except per share amount adjustment zimmer pension liability affecting spinoff zimmer net sales earnings discontinued operations follows earnings continuing operations discontinued operations dollars millions net earnings net gain disposal net sales earnings income taxes net earnings income taxes basic net earnings discontinued operations average common shares outstanding earnings continuing operations net earnings million reflected statement earn discontinued operations ings primarily reflects reduction tax contingency reserve related net earnings spinoff zimmer net gain disposal consolidated statement cash flows includes clairol zimmer businesses date disposition company uses centralized net earnings approach cash management financing operations accord diluted ingly company allocate debt businesses average common shares outstanding cash flows operating investing activities principally investing conversion convertible debt bonds discontinued operations years ended december incremental shares outstanding assuming million billion including approximately billion pro exercise dilutive stock options ceeds sale clairol respectively earnings continuing operations discontinued operations net earnings net gain disposal net earnings net earnings includes interest expense added back assumed conversion convertible debt common shares weightedaverage shares issuable upon exercise stock options included diluted earnings per share calculation dilutive million million million note expense net components expense net year ended december restated restated dollars millions interest expense interest income foreign exchange transaction loss net net expense net interest expense primarily related issuance billion debt billion commercial paper conjunction iiiii annual report bristolmyers squibb companynotes consolidated statements dupont pharmaceuticals imclone transactions addition effective tax rate continuing operations increased interest expense reduced net interestrate swap gains mil due primarily decrease effective tax rate bene lion million respectively interest income relates primarily cash cash fit operations ireland puerto rico switzerland equivalents investments marketable securities provisions certain nondeductible litigation reserves increase estimates contingent tax matters compared note income taxes components earnings loss continuing operations minor components current noncurrent deferred income tax assets ity interest income taxes liabilities december year ended december restated restated restated dollars millions dollars millions acquired inprocess research development us intercompany profit inventory items nonus foreign tax credit carryforward legal settlement restructuring acquisition divestiture reserves amounts categorized based location taxing deferred income authorities alternative minimum tax credit carryforward provisionbenefit income taxes attributable continuing opera charitable contribution carryforward tions consisted state tax net operating loss carryforward foreign net operating loss credit carryforward year ended december sales returns allowances restated restated research experimentation tax credit carryforward dollars millions postretirement pension benefits depreciation current deferred foreign currency gain us net nonus valuation allowance deferred tax assets net deferred us recognized nonus deferred income tax assets current deferred income tax assets noncurrent us foreign income taxes payable companys provision income taxes dif liabilities non current ferent amount computed applying statutory us federal income tax rate earnings continuing operations minority interest income taxes result following valuation allowance million december relates million foreign state net deferred tax assets million earnings eign state net operating loss tax credit carryforwards company minority interest income taxes currently believes likely remain unrealized future restated restated income taxes paid year million million dollars millions million respectively current tax benefit realized upon exercise stock options charged earnings continuing capital excess par value stock amounted million million operations million respectively minority interest company settled us federal income tax returns income taxes internal revenue service irs us statutory rate us federal income taxes provided substantially effect operations unremitted earnings nonus subsidiaries since managements practice ireland intent indefinitely postpone remittance total amount puerto rico net unremitted earnings nonus subsidiaries approximately bil switzerland lion december state local taxes company establishes liabilities possible assessments taxing author changes estimate ities resulting known tax exposures amounts represent reasonable contingent tax matters provision taxes ultimately expected paid may need adjusted nondeductible reserves time information becomes known december foreign certain tax contingencies liabilities established although company reasonably estimate possible amount bristolmyers squibb company annual reportiiiiinotes consolidated statements contingency possible contingencies could material periods company recognized revenue respect sales cardinal effect changes estimates related contingent tax matters included mckesson upon shipment product although company generally views rate reconciliation year ended december approximately one month supply desirable level wholesaler inventory company recognized income tax benefit million due settle goforward basis level wholesaler inventory representative ment certain prior year tax matters determination company industry average applying consignment model sales cardinal expected settlement tax litigation mckesson company defined inventory excess wholesalers ordi also company reorganized structure ownership nary course business inventory level inventory two weeks three many nonus subsidiaries principal purpose reorganization weeks supply respectively based levels inventory cardinal facilitate companys ability efficiently deploy financial resources mckesson required used basis negotiation incentives granted outside united states company believes reorganization trans march company entered distribution agreement actions generally taxfree inside outside united states mckesson provision warehousing order fulfillment services possible however taxing authorities particular jurisdictions could assert companys oncology therapeutics network otn specialty distributor tax liabilities arising reorganization transactions operations anticancer medicines related products terms agreement reorganized subsidiaries reasonably possible predict whether mckesson purchases oncology products service otns fulfillment needs taxing authority assert tax liability reasonably estimate pos number vendors including company subsequent shipment sible loss range loss respect asserted tax liability product mckesson company significant continuing involvement company would vigorously challenge assertion believes transaction including marketing product enduser invoicing would prevail assurance result company customer collecting receivables customer behalf prevail final nonappealable determinations possible mckesson addition otn keeps credit risk responsible impact could material shipping costs customer company accounts sales oncology products mckesson using consignment model defers recognition note revenue products sold mckesson receivables transactions resulted deferred revenue million mil major categories receivables follow lion december respectively company recognized december previously recorded deferred revenue net sales net dollars millions rebates returns adjustments approximately million million respectively accounts receivabletrade note accounts receivablemiscellaneous property plant equipment less allowances bad debts major categories property plant equipment follow receivables net december restated note inventories dollars millions major categories inventories follow land december buildings restated machinery equipment fixtures dollars millions construction progress finished goods less accumulated depreciation work process property plant equipment net raw packaging materials consignment inventory capitalized interest included categories property plant equip ment shown company capitalized interest million million years ended december respectively note consignment significant portion companys us pharmaceuticals sales made wholesalers april company disclosed experienced substantial buildup wholesaler inventories us pharmaceuticals busi ness several years primarily buildup primarily due sales incentives offered company wholesalers company accounts certain sales pharmaceutical products cardinal health inc cardinal mckesson corporation mckesson using consignment model based part relationship amount incentives offered wholesalers amount inventory held wholesalers company determined shipments product cardinal ship ments product mckesson met consignment model criteria set forth within note accounting policiesrevenue recognition july july respectively case continuing end period thereafter accordingly consignment model required applied shipments prior respective iiiii annual report bristolmyers squibb companynotes consolidated statements note december company two revolving credit facilities goodwill totaling billion aggregate support domestic commercial paper changes carrying amount goodwill years ended program facilities established september august december follows respectively syndicate lenders extendable anniversary date consent lenders one revolving credit facilities certain financial covenants company compliance pharmaceuticals nutritionals healthcare december borrowings outstanding revolving dollars millions segment segment segment total credit facilities december company unused balance december shortterm lines credit foreign banks million million purchase accounting adjustments december respectively change exit cost estimate purchase price allocation components longterm debt follows adjustments december balance december dollars millions restated notes due notes due note floating rate convertible debentures due intangible assets notes due intangible assets major asset class follows notes due debentures due december debentures due dollars millions debentures due yen notes due patentstrademarks yen notes due licenses euro interest yen principal term loan technology due industrial revenue bonds due less accumulated amortization yen notes due net carrying amount yen notes due variable rate industrial revenue bonds due amortization expense intangible assets majority capitalized leases included costs products sold years ended december million million million respectively expected amortization expense next five years related current balance intangible assets follows company issued billion debt follows face value effective years ending december dollars millions debt description dollars millions interest rates month libor convertible debt due callable strike price month libor notes due notes due yen notes due note yen notes due shortterm borrowings yen notes due longterm debt included shortterm borrowings amounts due foreign banks million million current installments longterm debt october company issued billion convertible debentures million million december respectively debentures pay interest quarterly annual rate equal month us commercial paper outstanding december us libor reset quarterly minus yield never less zero commercial paper outstanding december million final maturity september debentures callable par average interest rate commercial papers issued time september issuer holders also redeem fully repaid december proceeds com debentures par september mercial paper issuance used general corporate pur fundamental change ownership company occurs bond poses average interest rates international shortterm borrowings initial conversion price conversion rate shares current installments longterm debt outstanding december adjustable depending average closing prices applica respectively compared respectively ble period maximum conversion rate shares december bristolmyers squibb company annual reportiiiiinotes consolidated statements note company entered fixed floating interest rate swaps stockholders equity billion longterm debt cash payments interest million million million respectively changes common shares treasury stock capital excess par value stock restricted stock payments due period capital cost excess dollars millions total later years common treasury treasury par value restricted dollars millions shares issued shares stock stock stock longterm debt balance obligations included shortterm borrowings companys consolidated bal december ance sheet balances represent outstanding nominal longterm debt values december company provided financial guarantees issued pursuant form standby letters credit performance bonds majority stock plans standby letters credit us nuclear regulatory commission options massachusetts department public health relating companys conversions medical imaging manufacturing operations insurance companies preferred stock support thirdparty liability programs performance bonds relate amortization sale company product various foreign ministries health middle lapses restricted stock east company believes significant majority guarantees purchases expire without funded amounts obligations presented balance following table december expiration period less issued pursuant dollars millions total year years stock plans standby letters credit options performance bonds conversions guarantees preferred stock total commercial amortization commitments lapses restricted stock purchases balance december issued pursuant stock plans options conversions preferred stock amortization lapses restricted stock balance december share companys preferred stock convertible shares common stock callable companys option reductions number issued shares preferred stock due conversions shares common stock dividends declared per common share iiiii annual report bristolmyers squibb companynotes consolidated statements accumulated balances related component comprehen common share respectively date grant using blackscholes sive income loss follows optionpricing model following assumptions minimum accumulated available deferred loss pension foreign currency sale effective liability comprehensive dollars millions translation securities hedges adjustment incomeloss dividend yield balance volatility december riskfree interest rate restated assumed forfeiture rate comprehensive expected life years income loss balance stock option transactions december weighted restated average shares common stock exercise price comprehensive available shares income loss option plans plan plan balance balance december december authorized restated granted comprehensive granted result income loss zimmer spinoff balance exercised december lapsed balance december company expects recognize million deferred hedging losses authorized net earnings next twelve months granted exercised stock compensation plans lapsed companys stock incentive plan officers key employees balance december may granted options purchase companys common stock less authorized market price date option granted options gener granted ally become exercisable installments per year first exercised fourth anniversaries grant date maximum term lapsed years additionally plan provides granting stock appreciation balance december rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common effective spinoff zimmer august unexercised bristolmyers squibb stock option exercise price plan also provides granting stock options held zimmer employees converted zimmer stock options remaining unexercised bristolmyers squibb stock options number stock options exercise price performancebased stock options certain key executives adjusted preserve intrinsic value stock options ratio exercise price fair terms stock incentive plan authorized shares include value existed prior spinoff outstanding shares per year well number shares tendered prior year pay purchase price options num following tables summarize information concerning companys ber shares previously utilized satisfy withholding tax obligations upon exer stock compensation plans currently outstanding exercisable options cise shares available grant prior year granted year shares cancelled forfeited expired also available number number securities remaining future grant plan incorporates companys longterm performance securities issued weighted average available future issuance upon exercise exercise price equity compensation awards outstanding options outstanding options plans excluding securities addition stock incentive plan provides granting warrants rights warrants rights reflected column shares common stock key employees subject restrictions plan category b c continuous employment restrictions generally expire fiveyear period date grant compensation expense recognized restricted equity compensation period december respectively plans approved restricted shares outstanding plan security holders teamshare stock option plan fulltime employees excluding key executives granted options purchase companys common stock equity compensation market price date options granted company authorized plans approved shares issuance plan individual grants generally security holders become exercisable evenly third fourth fifth anniversary grant date maximum term years options shares exercised plan december fair value options granted esti mated per common share per common share per bristolmyers squibb company annual reportiiiiinotes consolidated statements options outstanding options exercisable reclassified comprehensive income income expenses weighted carrying amount companys financial instruments average weighted weighted includes cash cash equivalents marketable securities accounts receivable range remaining average average exercise number contractual exercise number exercise accounts payable approximates fair value december prices outstanding life price exercisable price longterm debt noted difference fair value carrying value material note segment information company organized pharmaceutical company related healthcare businesses four reportable segmentspharmaceuticals otn nutritionals healthcare pharmaceuticals segment comprised global pharmaceutical international excluding japan consumer medicines busi nesses otn segment specialty distributor anticancer medicines december shares common stock reserved related products otn previously included pharmaceuticals issuance pursuant stock plans options conversions preferred stock segment met quantitative thresholds reportable segment accordingly options related discontinued operations included amounts prior periods reclassified conform current year presentations material nutritionals segment consists mead johnson primarily infant formula business healthcare segment consists convatec medical note imaging consumer medicines us japan businesses financial instruments companys products sold principally wholesale retail trade company exposed market risk due changes currency exchange nationally internationally certain products also sold drug rates interest rates result company utilizes foreign exchange manufacturers hospitals clinics government agencies medical profes option forward contracts offset effect exchange rate fluctuations sion three wholesalers accounted approximately anticipated foreign currency transactions primarily intercompany inventory respectively companys total net sales sales purchases expected occur within next two years wholesalers accounted respectively companys company exposures net foreign currency denominated assets total net sales three wholesalers accounted approxi liabilities approximated million million december mately companys total net sales sales concentrated respectively primarily europe japan mexico pharmaceuticals segment canada worldwide sales selected products product categories follows foreign exchange option contracts forward contracts used hedge anticipated transactions companys primary foreign currency exposures year ended december relation us dollar euro canadian dollar japanese yen restated restated notional amounts companys foreign exchange derivative contracts dollars millions december million million respec tively derivatives majority qualify hedges future pharmaceuticals cash flows effective portion changes fair value temporarily recorded pravachol comprehensive income recognized earnings hedged plavix item affects earnings ineffective portion hedges reported earnings taxol occurs fair value option forward contracts liabilities paraplatin million million december respectively avaproavalide recorded accrued liabilities fair value foreign exchange sustiva contracts based yearend currency rates blackscholes model monopril case option contracts glucovance company uses derivative instruments part interest rate risk man glucophage xr agement policy derivative instruments used comprised principally fixed zeritzerit er floating rate interest rate swaps subject fairvalue hedge account coumadin ing treatment company entered several fixed abilify total revenue floating interest rate swap contracts several financial institutions videxvidexec notional amounts swaps billion billion tequin december respectively accordance sfas glucophage ir accounting derivative instruments hedging activities company rec serzone ognized net reduction interest expense million million reyataz respectively reflects benefit lower floating rate buspar obtained swap compared fixed rate underlying debt nutritionals swap contracts well underlying debt hedged recorded fair infant formulas value resulted increase current assets longterm debt healthcare million million december respectively swap ostomy contracts generally held maturity company use deriva cardiolite tive financial instruments speculative purposes wound therapeutics company reclassified losses million million comprehensive income earnings majority classified cost products sold gain million iiiii annual report bristolmyers squibb companynotes consolidated statements segment information business segments earnings minority interest net sales income taxes yearend assets restated restated restated restated restated dollars millions pharmaceuticals oncology therapeutics network nutritionals healthcare total segments corporateother total corporateother principally consists interest income interest expense certain administrative expenses allocations business segments certain cor porate programs corporateother also includes gain sales businessesproduct lines million million respectively accel erated depreciation million termination benefits exit costs million million respectively asset writedown impairment charge million million respectively upfront payments licensing agreements million downsizing rationalized operations facilities million litigation charges net million million million respectively also includes million asset impairment charge imclone pharmaceuticals segment includes charge acquired inprocess research development million million respec tively additionally pharmaceuticals includes litigation settlement income million upfront payment licensing agreement million million accelerated depreciation assets manufacturing facilities north america expected closed end million charge asset impairment million charge relocation expenses million charge retention bonus benefits also million deductions customer chargebacks related abandoned product lines included reduction net sales recorded corporateother assets include cash cash equivalents marketable securities goodwill certain assets capital expenditures depreciation dollars millions pharmaceuticals oncology therapeutics network nutritionals healthcare total segments corporateother total geographic areas net sales yearend assets restated restated restated dollars millions united states europe mideast africa western hemisphere pacific total bristolmyers squibb company annual reportiiiiinotes consolidated statements note changes benefit obligations plan assets december leases companys defined benefit postretirement benefit plans minimum rental commitments noncancelable operating leases primarily real estate effect december pension benefits benefits restated restated years ending december dollars millions dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected later years benefit obligation total minimum payments plan participants contributions less total minimum sublease rentals curtailments settlements net minimum rental commitments transfer dupont pharmaceuticals operating lease rental expense net sublease rental income million actuarial loss million million mil plan amendments lion million benefits paid exchange rate losses note benefit obligation pension postretirement end year benefit plans company certain subsidiaries defined benefit pension fair value plan assets plans defined contribution plans regular fulltime employees prin beginning year cipal pension plan bristolmyers squibb retirement income plan actual return plan assets funding policy contribute amounts provide current service employer contribution fund past service liability plan benefits based primarily years credited plan participants contributions service participants compensation plan assets consist principally settlements equity fixedincome securities transfer company also provides comprehensive medical group life benefits dupont pharmaceuticals substantially us retirees elect participate comprehensive transfer medical group life plans medical plan contributory contributions benefits paid adjusted periodically vary date retirement original retiring exchange rate gains company life insurance plan noncontributory plan assets consist princi fair value plan assets pally equity fixedincome securities similar plans exist employees end year certain countries outside us cost companys deferred benefits postretirement benefit plans funded status included following components unamortized net obligation pension benefits benefits adoption restated restated unrecognized prior service cost dollars millions unrecognized net actuarial loss net amount recognized service cost benefits earned year amounts recognized balance sheet consist interest cost projected prepaid benefit cost benefit obligation accrued benefit cost expected return plan assets intangible assets net amortization deferral accumulated net periodic benefit cost comprehensive income curtailments settlements net amount recognized total net periodic benefit cost several plans underfunded accrued benefit obligations exceeded company elected defer recognition medicare prescription accrued benefit liabilities december additional drug improvement modernization act time accumu minimum liabilities established increase accrued benefit liabilities lated postretirement benefit obligation net periodic postretirement benefit values underfunded accrued benefit obligations totaled cost reflect effect act retiree medical plan specific million million december respectively authoritative guidance accounting federal subsidy pending us unfunded benefit equalization plan us underfunded key international fasb guidance issued could require change previously plan plans uk japan canada belgium additional reported information minimum liability offset creation million intangible asset charges comprehensive income included stockholders equity million million december respectively iiiii annual report bristolmyers squibb companynotes consolidated statements accumulated benefit obligation defined benefit pension plans assumed health care cost trend rates december million million december respectively information pension plans accumulated benefit obligations excess plan assets health care cost trend rate assumed next year december rate cost trend rate assumed restated decline ultimate trend rate dollars millions year rate reaches ultimate trend rate projected benefit obligation assumed health care cost trend rates effect amounts accumulated benefit obligation reported health care plans onepercentagepoint change assumed fair value plan assets health care cost trend rates would following effects attributable primarily unfunded us benefit equalization plan percentage percentage several plans international markets unfunded us benefit equal dollars millions point increase point decrease ization plan provides pension benefits employees compensation irs limits funded taxadvantaged manner effect total service interest cost additional information pertaining companys pension postretire effect postretirement benefit obligation ment plans pension benefits benefits companys asset allocation pension postretirement benefits restated restated december dollars millions pension benefits benefits increase minimum restated restated liability included comprehensive income public equity securities weightedaverage assumptions used determine benefit obligations debt securities including cash december private equity pension benefits benefits restated restated total companys investment strategy emphasizes equities order achieve discount rate high expected returns long run low expense low required cash rate compensation increase contributions us pension plans target asset allocation pub lic equity us international private equity fixed weightedaverage actuarial assumptions used determine net periodic bene income maintained cash flow ie cash contributions benefit payments fit cost years ended december used rebalance back targets necessary investments diversified within three major asset categories us equity pension benefits benefits passively managed otherwise investments actively managed restated restated investment strategies international pension plans typically similar although asset allocations usually conservative bristolmyers squibb company common stock represents less discount rate plan assets december expected longterm return assets postretirement benefits commingled us pension plan plan assets assets therefore investment strategy identical described rate compensation increase us pension plans companys expected longterm rate return us pension plan assets contributions target asset allocation public equity us interna result improved investment returns significant contribu tional private equity fixed income approximated tions recent years current plan make cash contributions applying expected returns public equity private equity us pension plans significant tax deductible contributions likely fixed income target allocation actual historical returns allowed irs rules minimum contributions required also relevant annualized returns periods ended december contributions made us pension plans company may make years years years taxdeductible contributions h account retiree medical benefits us pension plan assets represented total company pension plan equal portion pension normal cost assets december disclosed total company contributions international pension plans expected expected return assets us pension plans due million range impact international pension plans typically employ less aggressive asset allocation expected return disclosed benefits relevant assets invested manner us pension plan assets international plan assets bristolmyers squibb company annual reportiiiiinotes consolidated statements estimated future benefit payments discloses claims among things hydrogen sulfate salt clopido following benefit payments reflect expected future service grel marketed plavix us patent dis appropriate expected paid closes claims among things use clopidogrel prevent dollars millions pension benefits benefits secondary ischemic event plaintiffs later withdrew patent lawsuit plaintiffs infringement position based defendants filing abbreviated new drug application anda fda seeking approval sell generic clopidogrel prior expiration composition matter patent defendants responded alleging patent invalid andor unenforceable cases consolidated discovery fact discovery closed october years teva pharmaceuticals usa teva generic drug manufacturer filed anda fda claiming patent relating plavix savings plan invalid two others infringed teva none patents principal defined contribution plan bristolmyers squibb savings involved pending patent infringement litigation involving plavix investment program companys contribution based employee teva filing challenge patent issue plavix litigation contributions level company match companys contributions therefore expected impact litigation plan million million million appear teva intends commercialize generic form plavix prior expiration termination patent issue litigation although note assurance continue case legal proceedings contingencies net sales plavix approximately billion expected various lawsuits claims proceedings investigations pending grow substantially next several years company anticipates company certain subsidiaries accordance sfas revenue growth important factor offsetting expected decreases accounting contingencies company records accruals contingen sales companys products recently experience cies probable liability incurred amount loss exclusivity losses period reasonably estimated matters involve antitrust securities patent currently company expects plavix market exclusivity infringement employee retirement income security act united states composition matter patent plavix found amended erisa pricing sales marketing practices environmental infringed invalid andor unenforceable district court level fda health safety matters product liability insurance coverage could approve defendants andas sell generic clopidogrel significant matters described generic competition plavix could begin company exhausted fourth quarter company established reserves liabilities appeals generic competition would likely result substantial decreases million comprised million relation wholesaler inventory sales plavix us issues certain accounting matters discussed although plaintiffs intend vigorously pursue enforcement securities matters million relation pharmaceutical pricing patent rights plavix possible time reasonably assess sales marketing practices discussed pricing sales come lawsuits company prevail lawsuits promotional practices litigation investigations possible timing potential generic competition plavix however generic time reasonably assess final outcome matters accordance competition occur company believes unlikely occur gaap company determined amounts represent mini sometime year also possible reasonably estimate mum expected probable losses respect groups matters eventual impact lawsuits company however loss market exclusiv losses related matters may exceed reserves impact ity plavix subsequent development generic competition would either one groups matters could material company material companys sales plavix results operations cash believe topend range losses estimated flows could material financial condition liquidity exception accruals taxol buspar environ mental product liability proceedings company established vanlevlitigation reserves matters described assurance april may june company former chairman board increase scope matters future lawsuits chief executive officer charles heimbold jr former chief scien claims proceedings investigations material management contin tific officer peter ringrose phd named defendants number ues believe previously disclosed next years aggre class action lawsuits alleging violations federal securities laws regulations gate impact beyond current reserves legal matters affecting actions consolidated one action us district court company reasonably likely material companys results operations district new jersey plaintiff claims defendants dissemi cash flows may material financial condition liquidity nated materially false misleading statements andor failed disclose mate rial information concerning safety efficacy commercial viability plavix litigation product vanlevduring period november april companys us territory partnership alliance sanofi may plaintiff submitted amended complaint adding allega plaintiff two pending patent infringement lawsuits instituted u tions company present chairman board chief executive district court southern district new york entitled sanofi officer peter r dolan former chairman board chief executive synthlabo sanofisynthlabo inc bristolmyers squibb sanofi officer charles heimbold jr former chief scientific officer peter pharmaceuticals holding partnership v apotex inc apotex corp cv ringrose phd disseminated materially false misleading statements rws sanofisynthlabo sanofisynthlabo inc bristolmyers andor failed disclose material information concerning safety efficacy squibb sanofi pharmaceuticals holding partnership v dr reddys laboratories commercial viability vanlevduring period april march ltd dr reddys laboratories inc cv rws similar proceed number related class actions making essentially allega ings involving plavix also instituted outside us tions also filed us district court southern district new suits filed march may respectively york actions transferred us district court based us patent composition matter patent district new jersey company filed motion partial judgment iiiii annual report bristolmyers squibb companynotes consolidated statements favor based upon pleadings plaintiff opposed motion part tors compensation alleged improper insider trading proceeds injunctive seeking amend complaint including another attempt expand relief fees costs expenses contribution certain officers alleged lia proposed class period court ruled companys motion bility consolidated securities class action pending us district dismiss plaintiffs motion leave amend discovery ongoing court southern district new york discussed contribu plaintiff purports seek compensatory damages costs expenses behalf tion indemnification pwc discovery taken mat shareholders ter december company moved dismiss consolidated possible time reasonably assess final outcome liti amended complaint two similar actions pending new york state court gation reasonably estimate possible loss range loss respect plaintiffs seek equitable relief damages costs attorneys fees litigation company prevail final nonappealable sec us attorneys office grand jury district determinations litigation impact could material new jersey investigating activities company certain current former members companys management connection securities matters wholesaler inventory issues referenced certain accounting period march may company number issues company cooperating investigations current former officers named defendants number possible time reasonably assess final outcome securities class action suits suits variously alleged violations federal litigations investigations reasonably estimate possible loss range securities laws regulations connection three different matters loss respect litigations investigations company pro vanlevas discussed ii sales incentives wholesaler inventory levels ducing documents actively cooperating investigations iii imclone imclones product erbitux discussed investigations could result assertion civil andor criminal claims allegations concerning vanlevhave transferred us district court company andor current former members companys manage district new jersey consolidated action pending ment company prevail final nonappealable determina remaining actions consolidated pending us district tions litigations investigations impact could material court southern district new york plaintiffs filed consolidated class action complaint april company certain current erisa litigation former officers alleging class period october march december first quarter company others consolidated class action complaint alleges violations federal named defendants five class actions brought erisa us securities laws connection among things companys invest district courts southern district new york district new ment relationship imclone imclones product erbitux jersey actions consolidated southern district new certain accounting issues addressed restatement including york caption bristolmyers squibb co erisa litigation issues related wholesaler inventory sales incentives establishment cv amended consolidated complaint alleging class period reserves accounting certain asset sales plaintiffs seek january march served august compensatory damages costs expenses august company amended consolidated complaint brought behalf four named plain moved dismiss consolidated class action complaint plaintiffs tiffs putative class consisting participants bristolmyers opposed companys motion dismiss company replied squibb company savings investment program savings plan motion remains pending court discovery matter stayed pur beneficiaries whose benefit savings plan held andor acquired company suant private securities litigation reform act addition action stock time class period excluding defendants heirs filed early october new york state court making similar factual predecessors successors assigns named defendants company allegations asserting variety claims including among others common bristolmyers squibb company savings plan committee committee law fraud negligent misrepresentation discovery taken thirteen individuals presently serve committee served matter january company moved dismiss complaint committee recent past charles heimbold jr peter r dolan beginning october number companys current former past present chief executive officer respectively company officers directors named defendants three shareholder derivative amended consolidated complaint generally alleges defendants suits pending us district court southern district new york breached fiduciary duties erisa class period among number companys current former officers directors things continuing offer company stock fund company stock named defendants three shareholder derivative suits filed period investment alternatives savings plan continuing invest march may us district court district company matching contributions company stock fund company new jersey july us district court district new jersey stock failing disclose investments company stock ordered three shareholder derivative lawsuits filed court allegedly imprudent savings plans purchases company stock transferred us district court southern district new york january alleged transactions prohibited erisa subsequently us district court southern district new york finally defendants heimbold dolan alleged breached ordered six federal shareholder derivative suits consolidated plaintiffs fiduciary duties erisa failing monitor actions filed consolidated amended verified shareholder complaint certain committee erisa claims predicated upon factual allegations similar members board directors current former officers raised securities matters concerning among pricewaterhousecoopers pwc companys independent auditors things safety efficacy commercial viability vanlev companys sales company nominal defendant consolidated amended complaint alleges incentives certain wholesalers inventory levels wholesalers among things violations federal securities laws breaches fiduci companys investment relations imclone imclones prod ary duty certain individual defendants connection companys uct erbitux alleged anticompetitive behavior connection conduct concerning among things safety efficacy commercial viabil busparand taxol ity vanlevas discussed companys sales incentives certain significant discovery october wholesalers inventory levels wholesalers companys invest company defendants moved dismiss amended ment relations imclone imclones product erbitux consolidated complaint plaintiffs opposed motion dismiss alleged anticompetitive behavior connection busparand taxol defendants replied possible time reasonably pre lawsuit also alleges malpractice negligent misrepresentation negligence dict final outcome reasonably estimate possible loss range loss pwc plaintiffs seek restitution rescission certain officers direc respect consolidated litigation company prevail bristolmyers squibb company annual reportiiiiinotes consolidated statements final nonappealable determinations matters impact could finally company defendant related state court proceedings com material menced new york new jersey california arizona tennessee pro ceedings attorney general pennsylvania federal court pricing sales promotional practices litigation investigations proceedings commenced counties suffolk westchester rockland company together number pharmaceutical manufactur new york collectively new york counties awp cases proceedings ers defendant several private class actions actions brought transferred awp multidistrict litigation pretrial purposes nevada montana attorneys general counties suffolk although plaintiffs california arizona new jersey actions sought westchester rockland new york pending federal state remand cases state courts california remand motions courts relating pricing certain company products federal cases denied arizona remand motion granted remand consolidated pretrial purposes caption motions remain pending new york counties awp cases allege rico pharmaceutical industry average wholesale price litigation mdl claims similar made amended master consolidated complaint us district court district massachusetts awp multidistrict awp multidistrict litigation however claims behalf litigation counties contributors new york states medicaid obligations defendants june court awp multidistrict litigation granted firstfiled suffolk county case moved dismiss amended com private plaintiffs motion leave file amended master consolidated plaint action oral argument heard motion december complaint amended master complaint amended master complaint ruling issued respect case remanded arizona contains two sets allegations company first alleges state court defendants filed motions dismiss stay hearing companys many pharmaceutical manufacturers reporting prices motionsis currently scheduled june merits discovery certain drug products listed drugs companys case effect stayed falsely overstating average wholesale price awp published industry cases preliminary stage company unable compendia turn improperly inflated reimbursement paid medical assess outcome possible effect business profitability providers others prescribed administered products second reasonably estimate possible loss range loss respect cases alleges company certain defendant pharmaceutical manu company prevail final nonappealable determinations facturers conspired one another program called together rx card litigations investigations impact could material program fix awps certain drugs made available consumers company together number pharmaceutical manufactur program amended master complaint asserts claims federal ers also received subpoenas document requests various gov rico antitrust statutes state consumer protection fair trade statutes ernment agencies seeking records relating pricing sales marketing amended master complaint brought behalf two main proposed practices best price reporting drugs covered medicare andor classes divided subclasses persons entities medicaid requests records come us attorneys office forward directly paid portion price listed drug district massachusetts office inspector general price calculated reference awp b contracted phar department health human services conjunction civil macy benefit manager provide others drugs listed amended division department justice office inspector general consolidated complaint ii persons entities office personnel management conjunction us attorneys ward paid reimbursed portion purchase price drug covered office eastern district pennsylvania several states addition together rx card program based whole part awp request information come house committee energy company defendants moved dismiss amended commerce connection investigation committee currently master complaint grounds fails state claims applicable conducting medicaid best price issues finally company received statutes motions denied february although court civil investigative demand attorney general state missouri dismissed one plaintiffs claims failure plead cognizable rico relating direct consumer advertising pravachol period enterprise accordingly company defendants required company also received notice putative class action lawsuit answer amended master complaint addition company involving issues filed february circuit court engaged continue engage discovery private class actions jackson county missouri kansas city captioned richard summers v bristol awp multidistrict litigation myers squibb company company served complaint nevada montana attorneys general complaints assert claims similar july company announced recently initiated amended master complaint state law also assert internal review certain sales marketing practices review claims name respective states alleged violations state focuses whether practices comply applicable antikickback laws medicaid fraud statutes nevada montana attorneys general cases also includes analysis practices respect compliance originally commenced respective state courts later best price reporting rebate requirements medicaid program removed awp multidistrict litigation attorney general moved certain us governmental programs reference medicaid rebate case remanded state court ground federal juris program ii applicable fda requirements company met diction june court awp multidistrict litigation ruled representatives us attorneys office district massachusetts nevada action company named remanded discuss review company received subpoena us state court ground defendants joined original attorneys office district massachusetts companys internal removal petition case proceeding nevada state court court review expected continue resolution pending governmental investi retained jurisdiction montana case defendants moved dismiss gations related matters montana second nevada case company named company producing documents actively cooperating oral argument heard motion december ruling investigations could result assertion civil andor criminal claims issued company unable assess outcome reasonably estimate possible loss range loss respect investigations could include imposition fines penalties administrative remedies andor liabil ity additional rebate amounts company prevail final nonappealable determinations litigations investigations impact could material iiiii annual report bristolmyers squibb companynotes consolidated statements ctlaig litigation product cases involving psychoses seizures cardiac injuries august repligen corporation repligen university company expects dismissed additional cases products michigan instituted lawsuit company us district court never used plaintiffs plaintiffs alleged injury occurred eastern district michigan suit alleged dr craig thompson three days ingestion ppa containing product formerly professor university michigan involved col plaintiff suffered cardiac injuries psychoses laboration certain companys scientists thompsons activ serzone serzonenefazodone hydrochloride antidepressant ity collaboration made rightful inventor several patents launched company may canada march company later obtained covering soluble forms ctla related methods united states december company added black box warning use conducting trial september district court ruled serzonelabel warning potential risk severe hepatic events including repligen university michigan failed prove thompson possible liver failure need transplantation risk death within made inventive contribution patents suit thus enti several months black box warning added package insert tled added sole joint inventor companys patents repligen serzone number lawsuits including several class actions filed university michigan appealed district courts decision company plaintiffs allege company knew known us court appeals federal circuit hepatic risks posed serzoneand failed adequately warn physi cians users risks seek compensatory punitive damages erbitux litigation medical monitoring refunds costs purchasing serzone october complaint filed yeda research present company lawsuits behalf plaintiffs development company ltd yeda imclone systems aventis pending federal state courts throughout united states pharmaceuticals inc us district court southern district twentyfour cases pending new york state court new york action alleges seeks three individuals associated consolidated pretrial discovery addition approximately yeda also named coinventors us patent alleged unfiled claims injury associated serzone august covers therapeutic combination egfr monoclonal antibody federal cases transferred us district court southern antineoplastic agents chemotherapeutic agents use treatment district west virginia serzone products liability litigation mdl cancer yedas action successful yeda could position practice although discovery still early stage appears license others practice invention could result product com cases involve liver failure june district court dismissed class petition erbitux might otherwise occur company claims two class action complaints although number party action unable predict outcome stage class action complaints filed company sought certification proceedings one personal injury classes remaining class action complaints seek certification personal injury classes january product liability litigation court issued order setting hearing class certification october company party product liability lawsuits involving allegations addition cases filed united states three national injury caused companys pharmaceutical overthecounter medica class actions filed canada tions majority lawsuits involve certain overthecounter medica stadolnsstadolns approved fda unscheduled tions containing phenylpropanolamine ppa companys serzoneand opioid analgesic nasal spray february company asked fda stadolns prescription drugs addition lawsuits company also faces schedule stadolns schedule iv low potential abuse drug due unfiled claims involving products postmarketing reports suggestive inappropriate use product ppa may yale university published results hemorrhagic october became schedule iv drug since company stroke project concluded evidence suggestion received number lawsuits involving stadol late number ppa may increase risk hemorrhagic stroke limited population filed suits increased due newly passed tort reform legislation november fda issued public health advisory requested became effective january plaintiffs manufacturers ppacontaining products voluntarily cease manufacturing new suits previously asserted claims company alleged marketing time ppacontaining products manufactured injuries sold company comtrexliquid gel formulations company currently party cases pending behalf total naldecon november company well man approximately plaintiffs federal state courts throughout united ufacturers ppa containing products discontinued manufacture mar states plaintiffs claim company committed fraud fda keting ppa containing products allowed customers return unused wrongfully promoted stadolns nonaddictive plaintiffs allege product possession company failed adequately warn addiction dependency risk january company served first ppa lawsuit associated use stadolns addition lawsuits company currently defendant approximately personal injury law approximately alleged unfiled claims approximately suits filed behalf approximately plaintiffs federal state courts active majority cases claims pending mississippi throughout united states majority lawsuits involve multiple addition cases filed united states two class actions defendants among claims plaintiffs allege ppa causes hemorrhagic one individual case filed canada ischemic strokes defendants aware risk failed warn consumers failed remove ppa products plaintiffs seek com breast implant litigation pensatory punitive damages federal cases transferred company together subsidiary medical engineering corporation us district court western district washington mec certain companies remains defendant number claims phenylpropanolamine ppa products liability litigation mdl lawsuits alleging damages personal injuries various types resulting district court denied motions class certification class polyurethanecovered breast implants smoothwalled breast implants action lawsuits pending company litigation formerly manufactured mec related company vast majority june district court issued ruling effectively limiting claims company direct lawsuits resolved settle plaintiffs claims hemorrhagic ischemic strokes rulings favorable ments trial likewise claims potential claims company regis defendants included inadmissibility expert testimony cases alleging tered nationwide class action settlement approved federal district injuries occurring three days ingestion ppa containing court birmingham alabama revised settlement bristolmyers squibb company annual reportiiiiinotes consolidated statements resolved revised settlement company established accruals claims matters settled required court respect breast implant product liability litigation company believes approval given final approval supervising court total possible loss addition amounts accrued material amount settlements million amount million company intends vigorously defend product liability lawsuits accrued million accrued remaining believes majority cases claims without merit million accrued possible time reasonably assess final outcome companys ftc also opened investigation relating buspar matter pending product liability lawsuits unfiled claims certainty manage settled entry consent decree effect april ment opinion ultimate disposition matters material adverse effect companys financial position environmental proceedings company believes adequate selfinsurance reserves commercially following discussion describes environmental proceedings available excess insurance cover potential loss related product liability governmental authority may involve potential monetary sanctions cases claims threshold prescribed specific sec rule ii civil action environmental claim could result significant liabilities iii platinollitigation updates ongoing matters resolution matters disclosed february class action complaint filed north shore recent public filings iv summary environmental remediation costs hematologyoncology associates pc company us preliminary results internal audit performed companys district court district columbia putative class action facility hopewell nj indicate operations sites wastewater treat brought behalf direct purchasers platinolthat alleges company ment plant related discharges may compliance new jersey violated federal antitrust laws maintaining monopoly us market water pollution control act implementing regulations terms allegations focus companys actions concerning us patent companys discharge permits company reported findings patent including procurement patent submis new jersey department environmental protection njdep february sion information relating patent listing orange book currently engaged settlement discussions state none initiation previous lawsuits potential generic manufacturers based results audit suggest adverse impact public patent plaintiffs seek declaratory judgment damages including health company taken continue take corrective actions treble damages address identified deficiencies prevent future occurrences company markets platinolunder exclusive patent licenses research january njdep sent company approximately five corporation technologies rct companies information request letter relating site north brunswick federal trade commission ftc also opened investigation relating township nj waste materials er squibb sons squibb platinol matter settled entry consent decree wholly owned subsidiary bms may disposed effect april fill material containing industrial waste heavy metals possible time reasonably assess final outcome liti excess residential standards discovered fall expansion gation reasonably estimate possible loss range loss respect project north brunswick township high school school board litigation company prevail final nonappealable township current owners site preparing submit determinations litigation impact could material workplan njdep asked company contribute cost remediation company discussions njdep site owners taxollitigation potentially responsible parties site investigation ongoing number putative class actions brought claims asserted company company alleging antitrust consumer protection similar claims september njdep issued administrative enforcement concerning companys actions obtain enforce patent rights relating directive notice new jersey spill compensation control taxol number state attorneys general brought similar claims act requiring company approximately companies perform certain insurers asserted similar claims without filing suits matters assessment natural resource damages implement unspecified settled required court approval given final interim remedial measures restore conditions lower passaic river approval supervising court total amount settlements directive alleges company liable historically sent bulk million amount million accrued remaining waste former inland chemical company facility newark new jersey million accrued releases hazardous substances facility migrated ftc also opened investigation relating taxol matter newark bay continue adverse impact lower passaic river settled entry consent decree effect april watershed subsequently us environmental protection agency usepa additional case based allegations brought small also issued notice letter us comprehensive environmental generic drug manufacturer company moved dismiss case response compensation liability act cercla numerous parties court granted motion july plaintiff sought reconsidera including bmsseeking cooperation study conditions tion decision unsuccessful plaintiff filed notice substantially stretch passaic river subject njdeps appeal us court appeals seventh circuit possible directive usepa estimates study cost million study may also time reasonably assess final outcome suit reasonably esti lead cleanup actions directed usepa army corps engineers mate possible loss range loss dismissal reversed dis extent liability either directive usepas notice letter missal reversed company prevail final yet determined although company believe bms nonappealable determination action impact could material caused contributed contamination lower passaic river water shed company informed njdep willing discuss alle busparlitigation gations company njdep directive states number putative class actions brought responsible parties cooperate njdep may perform damage company alleging antitrust consumer protection similar claims concern assessment restoration take civil action recover remedial costs tre ing companys actions obtain enforce patent rights relating ble damages administrative costs penalties buspar number state attorneys general brought similar claims certain insurers generic drug manufacturers chain drug stores asserted similar iiiii annual report bristolmyers squibb companynotes consolidated statements october michigan department environmental quality mitted case willful misconduct knowing violation criminal law mdeq sent company letter violation lov alleging improper personal benefit permitted laws state delaware unspecified period time emissions certain digestion tanks mead company many years purchased directors officers insurance cov johnsons zeeland michigan facility exceeded applicable limit facilitys erage cover claims made directors officers amounts renewable operating air permit lov requires company take correc types coverage varied period period dictated market condi tive action submit compliance program report although mdeq tions various excess policies provide additional coverage liti demanded fines penalties enforcement action could result gation matters regulatory actions described involve certain penalties injunctive relief company contesting allegations companys current former directors officers covered lov aforementioned indemnity applicable certain prior period insurance july njdep advised squibb believed company vio policies however certain indemnification payments may covered lated clean air act failing comply prevention significant companys directors officers insurance coverage company deterioration requirements connection replacement gas turbine predict certainty extent company recover companys cogeneration facility new brunswick new jersey facil insurers indemnification payments made connection litigation ity december company settled matter matters regulatory actions described njdep signing administrative consent order requires july one companys insurers federal insurance company submit permit application creating facilitywide emissions cap company filed lawsuit new york supreme court company pay administrative fine approximately several current former officers members board directors seek may environmental quality board puerto rico issued ing rescission alternative declarations allowing federal avoid pay notice bristolmyers squibb alleging five violations federal resource ment certain directors officers insurance policies certain recovery conservation act relating recordkeeping storage require fiduciary liability insurance policies respect potential liability arising ments hazardous wastes companys facility humacao based connection matters described vanlevlitigation prior dealings eqb technical nature alleged violations securities matters erisa litigation sections discovery company believes penalties imposed significant taken matter october another companys insur company one several defendants class action suit filed supe ers sr international business insurance co ltd sri informed company rior court puerto rico february residents alleging air emis intended try avoid certain insurance policies issued company sions government owned operated wastewater treatment facility grounds alleged material misrepresentation nondisclosure barceloneta caused respiratory ailments violated local air rules initiated arbitration proceedings london england sri indicated company believes wastewater discharges treatment facility mate intends rely upon allegations similar described rial compliance terms companys permit company believes securities matters section support avoidance action litigation resolved immaterial amount nevertheless possible time reasonably assess final outcome matters suit still initial stage event adverse judgment reasonably estimate possible loss range loss respect matters companys ultimate financial liability could significantly greater antici company prevail final nonappealable determinations pated matters impact could material company also responsible various state federal foreign note laws including cercla certain costs investigating remediating con subsequent events tamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third par december company confirmed mead johnson wholly ties company estimates costs based information obtained owned subsidiary company reached agreement novartis ag usepa relevant agency andor studies prepared independent con novartis sell novartis adult nutritional business terms sultants including total estimated costs site expected cost agreement novartis acquire brands trademarks patents intel sharing potentially responsible parties prp company lectual property rights mead johnson global adult medical nutrition busi accrues liabilities probable reasonably estimable ness million including million contingent product company estimates share total future costs sites approxi conversion million upfront payment supply agreement mately million represents sum best estimates sim transaction closed february pretax gain approximately ple estimate reasonably made estimates minimums costs million expected recorded first quarter without taking account potential recoveries parties adult nutritional products recorded sales million currently expected company paid less million exclud company announced january agreed acquire ing legal fees last five years investigation remediation acordis specialty fibres acordis privately held company based united matters including liabilities cercla onsite remedia kingdom licenses patent rights supplies materials convatec tions wound therapeutics line transaction subject regulatory approval although possible predict certainty outcome granted transaction completed company environmental proceedings ultimate costs remediation company expects record inprocess research development charge believe reasonably possible expenditures company million million may incur excess existing reserves material adverse effect fda approved bla erbitux anticancer agent business financial position results operations company developing partnership imclone february erbitux injection use combination irinotecan treatment indemnification officers directors patients egfrexpressing metastatic colorectal cancer refrac companys corporate bylaws require except extent permit tory irinotecanbased chemotherapy use single agent treat ted law company shall indemnify officers directors judg ment patients egfrexpressing metastatic colorectal cancer ments fines penalties amounts paid settlement including legal fees intolerant irinotecanbased chemotherapy accordance agreement appeals incurred connection civil criminal actions proceedings company paid imclone march million milestone pay relates services company subsidiaries bylaws ment approval erbitux fda provide limit amount indemnification indemnification per bristolmyers squibb company annual reportiiiiinote selected quarterly financial data unaudited selected quarterly financial data revised reflect restatement discussion restatement see note restatement previously issued financial statements years ended december first quarter second quarter third quarter previously previously previously dollars millions except per share data reported restated reported restated reported restated net sales gross margin net earnings earnings per common share basic diluted dividends declared per common share cash cash equivalents marketable securities first quarter second quarter third quarter previously previously previously dollars millions except per share data reported restated reported restated reported restated net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities note earnings per share quarters may add amounts year period computed discrete basis includes litigation settlement charges million million second fourth quarters respectively first second third quarters includelitigation settlement income million million million respectively first second third fourth quarters include provisions restructuring items million million million mil lion respectively second third fourth quarters include reversals prior period restructuring items million million million respectively third fourth quarters include upfront payments licensing agreementsof million million respectively includes gain sale product lines million first quarter first third fourth quarters include writeoffs acquired inprocess research development million million million respectively second fourth quarters includeprovisions restruc turing items million million respectively first third quarters include reversals prior period restructuring andother items million million respectively litigation settlement charges million million included first third quarters respectively also third quarter includes million asset impairment charge imclone principal corrections restatement discussed note restatement previously issued financial statements years ended december intercompany foreign exchange gains losses first quarter previously disclosed wic rebates accrual second quarter previously disclosed minority interest tax adjustment third quarter well intercompany foreign exchange gains losses income taxes vacation accrual third quarter iiiii annual report bristolmyers squibb companyfourth quarter year dollars millions except per share data reported reported net sales gross margin net earnings earnings per common share basic diluted dividends declared per common share cash cash equivalents marketable securities fourth quarter year previously previously dollars millions except per share data reported restated reported restated net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities common equivalent shares excluded computation diluted earnings per share effect would antidilutive follows millions third second third fourth quarter quarter quarter quarter year first quarter discontinued operations results included purchase price adjustment related clairol transaction million million net tax third quarter discontinued opera tions results included litigation provision million million net tax gain adjustment relating clairol transaction million million net tax fourth quarter dis continued operations results included million reduction provision income taxes due reduction tax contingency reserve related zimmer spinoff principal corrections interim periods restatement discussed note restatement previously issued financial statements years ended december intercompany foreign exchange gains losses third quarter goods transit adjustments provisions income taxes fourth quarter bristolmyers squibb company annual reportiiiiireport management report independent accountants management responsible preparation presentation integrity board directors financial information presented report accompanying consolidated stockholders financial statements prepared conformity accounting principles bristolmyers squibb company generally accepted united states america applying certain estimates judgments required managements opinion consolidated financial opinion accompanying consolidated balance sheet related statements present fairly companys financial position results operations consolidated statements earnings comprehensive income retained earnings cash flows cash flows present fairly material respects financial position company maintains system internal controls procedures provide bristolmyers squibb company subsidiaries december reasonable assurance transactions properly authorized results operations cash flows three appropriately recorded reported financial statements company years period ended december conformity accounting assets adequately safeguarded system consists part careful principles generally accepted united states america financial selection training development financial managers dissemination statements responsibility companys management responsibility written internal accounting policies organizational structure segregates express opinion financial statements based audits responsibilities companys internal auditors continually evaluate ade conducted audits statements accordance auditing standards quacy effectiveness system internal accounting policies procedures generally accepted united states america require plan controls actions taken correct deficiencies identified perform audit obtain reasonable assurance whether financial set forth companys standards business conduct ethics statements free material misstatement audit includes examining companys pledge company committed adhering highest test basis evidence supporting amounts disclosures financial standards moral ethical behavior business activities statements assessing accounting principles used significant estimates pricewaterhousecoopers llp companys independent accountants made management evaluating overall financial statement presentation audited annual financial statements accordance auditing standards gener believe audits provide reasonable basis opinion allyaccepted united states america report appears described note restatement previously issued financial statements audit committee board directors composed solely outside years ended december company restated previously directors meets regularly internal auditors independent accountants issued financial statements management review accounting auditing internal control structure described note accounting policies company changed financial reporting matters internal auditors independent accountants method accounting business combinations goodwill arising full free access audit committee transactions consummated subsequent june changed method accounting goodwill arising transactions consummated prior july impairment longlived assets peter r dolan chairman board chief executive officer philadelphia pennsylvania march andrew rj bonfield senior vice president chief financial officer march iiiii annual report bristolmyers squibb companyfiveyear financial summary fiveyear financial summary revised reflect restatement discussion restatement see note restatement previously issued financial statements years ended december restated restated restated restated dollars millions except per share data income statement data net sales earnings continuing operations minority interest income taxes earnings continuing operations earnings continuing operations per common share basic diluted average common shares outstanding basic diluted dividends paid common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securities longterm debt stockholders equity company recorded several items affected comparability results set forth table managements discussion analysis financial condition results operationsearnings years discussion items see managements discussion analysis financial condition results operationsnet sales note alliances investments note restructuring items note acquisitions divestitures note discontinued operations restatement adjustments affecting years set forth following table previously previously dollars millions reported restated reported restated net sales earnings continuing operations earnings continuing operations per common share basic diluted financial position data december total assets stockholders equity restatement adjustments affecting years adjustments respect net sales intercompany foreign exchange gains losses international pension employee benefit plan accrual income taxes restatement items described note restatement previously issued financial statements includes discontinued operations years bristolmyers squibb company annual reportiiiiiboard directors robert e allen louis v gerstner jr retired chairman chief executive officer retired chairman chief executive officer att corporation abd ibm corporation bd lewis b campbell laurie h glimcher md chairman president chief executive officer professor medicine immunology textron inc abc harvard medical school harvard school public health ab vance coffman leif johansson chairman chief executive officer president ab volvo chief executive officer lockheed martin corporation ac volvo group ab peter r dolan james robinson iii chairman chief executive officer chairman chief executive officer bristolmyers squibb company rre investors bcd ellen v futter louis w sullivan md president president emeritus american museum natural history b morehouse school medicine ac audit committee b committee directors corporate governance c compensation management development committee executive committee executive committee peter r dolan chairman chief executive officer lamberto andreotti anthony c hooper senior vice president president international president us pharmaceuticals stephen e bear tamar howson senior vice president human resources senior vice president corporate business development andrew g bodnar md john l mcgoldrick senior vice president strategy executive vice president general counsel medical external affairs james b palmer md frcp andrew r j bonfield chief scientific officer senior vice president chief financial officer president pharmaceutical research institute wendy l dixon phd elliott sigal md phd president global marketing senior vice president global clinical chief marketing officer pharmaceutical development donald j hayden jr john l skule executive vice president president americas senior vice president corporate environmental affairs iiiii annual report bristolmyers squibb companys c k h l e r n f r n common stock dividend reinvestment plan environment foundation copyright bristolmyers squibb mission ticker symbol bmy registered stockholders stock diversity reports bristolmyers squibb company new york stock exchange must held name copies companys rights reserved companys mission pacific stock exchange hold shares recent reports product names appearing companys stock may participate bristolmyers squibb foundation throughout italics extend enhance human life annual meeting stockholderpaid dividend sustainabilityenvironmental bold caption copy providing highestquality pharmaceutical stockholders reinvestment plan drip programs diversity registered trademarks tuesday may includes safekeeping efforts write bristolmyers squibb company related health care products hotel dupont saleofstock feature corporate affairs one subsidiary companies th market streets hold fewer shares bristolmyers squibb company global products referred wilmington de still eligible participate park avenue herein registered pledgeto patients customers safekeeping saleofstock new york ny approved us trademarks unless stockholder features well direct specifically noted otherwise employees partners services programs registration option copies companys abilifyis trademark otsuka inquiries concerning eeo reports available pharmaceutical company ltd shareholders neighbors adenoscanis trademark stockholder accounts stock stockholders upon written fujisawa healthcare inc world serveto act belief transfer matters including free copy companys request address avapro avalide plavixand address changes elimination annual report securities iscoverare trademarks sanofi priceless ingredient every product duplicate mailings dividend exchange commission information interest synthlabo sa reinvestment see next column fiscal year stockholders potential corzide delestrogencorgard honor integrity maker direct deposit dividends ended december investors including information florinefare trademarks king directed visit wwwbmscominvestors companys products pharmaceuticals inc erbituxis trademark companys transfer agent programs also available imclone systems incorporated registrar reports may also companys web site glucophage ir glucophage mellon investor services obtained sending request wwwbmscom xr glucovanceand metaglipare challenger road secretary registered trademarks merck ridgefield park nj bristolmyers squibb company sant sas associate merck wwwmelloninvestorcom park avenue kgaa darmstadt germany within us new york ny moisturel duricefand estrace trademarks galen chemicals outside us limited tdd telephone service solageis trademark hearing impaired galderma sa within us vaniqais trademark women outside us first healthcare inc viactivis trademark mcneil ppc inc cover keiichi nagano sturgis michigan pictured wife reiko keiichi colorectal cancer patient enrolled clinical trial erbitux cetuximab help fight cancer opposite top melody vernali process scientist bristolmyers squibb pharmaceutical research institute wallingford connecticut working colleagues create next generation anticancer therapies designed photographed written typeset bristolmyers squibb corporate affairs department printed recycled paperbristolmyers squibb company annual report nopqr f c u park avenue new york ny telephone wwwbmscom